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ABSTRACT 
Previous work on the binding of resting platelets to the 
basement membrane glycoprotein, laminin, has identified the 
Ic/IIa integrin c01aplex (CD49f/CD29), also known as VLA-6, 
as the receptor. There exists however, another protein with 
a molecular weight of 67kDa, that mediates this function on 
other cells. It is abundantly expressed on the membranes of 
breast cancer cells, where it plays a key role in both the 
localisation at, and penetration of vascular beds, by 
metastases. 
The objectives of this study were: 
- The development of a micro-titre assay similar to those 
used in previous studies, standardised and calibrated to 
characterize the adhesion of unstimulated normal human 
platelets to lamini~-coated surfaces. 
To determine the effect on adhesion of platelet 
activation, enzymatic surface-glycoprotein removal, 
antibodies to specific receptors and interaction with other 
adhesive proteins known to bind to platelet membranes. 
- To establish thE: in vivo relevance of the experimental 
findings, by the assay of adhesion of glycoprotein IIb/IIIa-
deficient platelets of two patients with Glanzmann's 
Thrombasthenia. 
These studies served to distinguish specific binding sites 
for laminin from t~e known surface receptors of platelets. 
The methodology used to isolate laminin receptors from the 
membranes of breast carcinoma cells was then applied to 
platelet concentrates. Membranes were obtained by 
centrifuging the ultrasonic lysate of a unit of platelets. 
These were solubii. i zed and passed over a laminin-Sepharose 
column. The bound components were eluted and identified by 
means of SOS-gel electrophoresis, after which a concentrate 
IX 
was tested for laminin binding by means of dot-blot 
methodology. 
The principle contribution of this work is the finding of a 
67kDa receptor for laminin on the surface membranes of 
platelets. 
The combination of the various approaches applied to 
characterise the adhesion of platelets to laminin, show that 
this is a specific.:::, Mg2+-dependent process, inhibited by 
ca2+ and not enhanced by platelet activation. Adhesion was 
decreased by proteolysis with trypsin and chymotrypsin, 
showing that the adhesion is mediated by a surface 
glycoprotein. Proteolysis with the Serratia marcescens 
metalloprotease, which cleaves off glycoprotein lb, did not 
affect adhesion, proving that this well known receptor for 
platelet adhesion is not involved in the adhesion. The 
receptors GPIV and glycocalicin were also excluded, as the 
presence of antibodies to these receptors had no effect. 
Prior incubation with fibrinogen or von Willebrand factor, 
which binds to specific receptors on the platelet membrane, 
inhibited adhesion, most likely due to spatial interference 
with the receptor site for laminin. The presence of the 
tetrapeptide recognised by the membrane receptors for many 
adhesive proteins, RGDS, at concentrations of up to lmM, had 
no effect. The platelets of the two subjects with 
Glanzmann's Thrombasthenia adhered normally, definitively 
ruling out the involvement of GPIIb/IIIa, which is absent 
from these plateleta. 
The isolation process recovered a membrane component from 
the laminin-Sepharose column with an elution pattern 
identical to that for the well characterised 67kDa receptor 
for laminin on the surface of breast carcinoma cells. They 
have the same mole8ular weights in both the reduced (67kDa) 
and non-reduced (53kDa) states. Blot identification 
• 
demonstrated laminin binding by the eluate. 
X 
In the last part of the work, collaborative studies using 
more sophisticated methodology have confirmed that platelet 
receptors for laminin play a role in their adhesion to 
living tissue. Anti-laminin Fab antibodies significantly 
decreased the adhesion when whole blood was perfused over 
isolated rabbit aortic segments. That these receptors are 
identical to the 67kDa receptor of breast carcinoma cells 
was shown by the specific, high affinity binding of 
antibodies directed at the carcinoma receptors to the 
surface of platelets when examined by flow cytometry. In 
addition, they inhibit platelet adhesion by 50-60% in the 
micro-titre assay. 
It is proposed that both the VLA-6 and the 67kDa receptors 
are required for platelet adhesion to laminin, possibly as a 
two stage process, similar to the systems for adhesion to 
von Willebrand factor, where binding is initially to GPib, 
followed by binding to GPIIb/IIIa. The possible relevance of 
this receptor in the pathophysiology of the metastatic 
process is discussed. 
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I. LITERATURE REVIEW 
PLATELET INTEGRINS AS ADHESIVE RECEPTORS 
Integrins are a family of transmembrane glycoprotein 
receptors, comprised of noncovalent alpha/beta heterodimer 
protein complexes. They derive their name from Hynes {1987), 
who described this superfamily of adhesion receptors which 
are structurally, immunologically and functionally related. 
Their prime function is to integrate cell signals between 
the cytoskeleton and the extracellular matrix. They 
participate in major biological processes in which cell to 
matrix and cell to cell adhesion is operative: embryological 
development; haemostasis and thrombosis; wound healing; 
immune and non-immune defense mechanisms; oncogenic 
transformation and invasion. 
Each member of the superfamily has a unique alpha and one of 
three beta subunits, designated beta1_3 . Integrins with 
beta1 and beta2 subunits are important receptors of the 
platelet membrane: 
A. THE VLA FAMILY 
The members of this family share the beta1 subunit. These 
receptors were first described on activated T lymphocytes 
after several weeks of in vitro stimulation with antigen, 
and thus termed very late antigens {VLA). With the use of 
VLA-specif ic monoclonal antibodies, the platelet membrane 
glycoproteins GPIIa, GPia and GPic were demonstrated to form 
heterodimers similar to the VLA receptors for matrix 
proteins on activated lymphocytes (Pischel et al, 1988). 
Each alpha subunit possesses a signal peptide followed by a 
long extracellular fragment with seven homologous repeating 
domains towards the amino terminus, a single transmembrane 
domain and a short cytoplasmic sequence {Takada and Hemler, 
1989) Platelet receptors within this group include: 
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1. The Collagen Receptor - VLA-2 (CD49b/CD29) 
The complex of Glycoprotein Ia (CD49b) and IIa (CD29) is 
involved in the adhesion of platelets to collagen (Santoro, 
1986). With the use of an antibody to the receptor of 
fibroblasts for this protein, inhibition of platelets to 
type I and type III collagen was found (Kunicki et al, 
1988). Structural homology to the fibroblast collagen 
receptor was also demonstrated by peptide mapping. The 
binding of purified GPia-IIa to collagen is Mg2+-dependent 
(Staatz et al, 1989). When platelets adhere to collagen 
through VLA-2, they undergo activation and granule 
secretion. Its physiologic role in haemostasis was confirmed 
by studies of a family with a selective deficiency of VLA-2 
who presented with an inherited bleeding syndrome 
(Nieuwenhuis et al, 1985). Defective platelet-collagen 
interaction was demonstrated (Nieuwenhuis et al, 1986). 
However, other rec,aptors and plasma factors appear to be 
involved in the adhesion of platelets to collagen as well 
(Coller et al, 1989): In the presence of plasma, antibodies 
to the GPia/GPIIa complex, together with antibodies to the 
fibrinogen receptor GPIIb/IIIa, inhibited adhesion 
incompletely, but to a greater degree than either of the 
antibodies alone. A two-step, two-site model for collagen-
induced cell signalling, adherence, activation and secretion 
has been proposed ( Santoro et al 1991) . It involves both 
VLA-2 and a signal-transducing receptor. GPIV ( see below) 
may be involved in the signal transduction phase 
2. The Fibronectin Receptor - VLA-5 (CD49e/CD29) 
The complex of glycoprotein Ic (CD49e; MW 165,000) and IIa 
(CD29; MW 145,000) has been identified as the mediator of 
adhesion of unactivated platelets to fibronectin (Piotrowicz 
et al, 1988). The complex corresponds to VLA-5 (Fischel et 
al, 1988), which is identical to the fibroblast fibronectin 
receptor (Takada et al, 1987, Wayner et al, 1988). The 
latter authors have demonstrated that antibodies to this 
3 
receptor of fibroblasts, inhibited the adhesion of platelets 
to fibronectin-coated micro-titre plates and precipitated 
with glycoprotein Ia (alpha subunit) and glycoprotein Ila 
(beta subunit). 
3. The Laminin Receptor - VLA-6 (CD49f/CD29) 
A complex of GPic (CD49f) and Ila (CD29) which have similar 
but unique structural properties to VLA-5, was identified on 
fibroblasts as the VLA-6 receptor (Hemler et al, 1988). VLA-
6 complexes have been identified on platelet membranes which 
bind to Sepharose columns to which the E8 fragment of the 
laminin molecule is linked (Sonnenberg et al, 1991). 
Platelet adhesion to laminin-coated micro-titre plates was 
inhibited in the presence of monoclonal antibodies to VLA-6 
(Sonnenberg et al, 1988). These studies are reviewed later. 
B. THE CYTOADHESIN FAMILY 
Members of this family share the beta3 subunit and are found 
in abundance on the membranes of platelets, endothelial 
cells, smooth muscle cells, monocytoid cells and fibroblasts 
(Ginsberg et al, 1988). 
1. Glycoprotein IIb/IIIa (CD41a) 
This is a non-covalent: heterodimer, comprised of two non-
identical components, GPIIb (CD41b), the alpha subunit with 
the higher molecular weight and GPIIIa (CD61) the beta 
subunit with th€. lower molecular weight. Both are 
synthesized as single chain polypeptides and processed by 
intracellular proteolysis to form two-chain molecules 
consisting of a heavy chain and a light chain. 
GPIIb has a molecular weight of 140kDa on polyacrylamide gel 
electrophoresis. Ctle to extensive intrachain disulphide 
bonds, the molecular weight of GPIIIa increases on reduction 
(Phillips and Agin, 1977a, 1977b), from 95kDa to 108kDa. 
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Both are found as components of a single immunoprecipitate 
on crossed immunoelectrophoresis (CD4la} of normal platelet 
membrane extracts ;Hagen et al, 1980). They also co-purify 
on affinity chromatography in Triton X-100 when using an 
immobilized monoclonal antibody directed towards one of them 
(McEver et al, 1983). Both are genetically absent from the 
platelets of patients with the inherited bleeding disorder -
Glanzmann's Thrombasthenia, characterized by the absence of 
aggregation. 
Approximately 50,000 copies of the GPIIb/IIIa complex are 
expressed on each platelet, constituting 15-20% of the total 
membrane protein. Two domains are found on rotatory 
shadowing electron microscopy: a globular head domain with 
two rod-like tails extending from either side (Carrell et 
al, 1985). 
GPIIb/IIIa has a number of functions: 
It carries the unique determinant 
alloantigen, PLAl (Newman et al 1989); 
for the human 
it is the receptor for fibrinogen, which is greatly 
enhanced following ADP activation (Gogstad et al, 1982). As 
reviewed by Peerschke (1985), this site is unavailable on 
resting platelets; 
Four sequences of 12 amino acids each, similar to the 
calcium-binding turns of calmodulin have been identified 
within GPIIb, and have been predicted to be the ca2+-binding 
sites for the GPIIb/IIIa complex (Penez et al, 1987). 
Studies defining the molecular alterations of GPIIb/IIIa 
following on ADP stimulation to induce fibrinogen binding, 
have been reviewed by Berndt and Caen (1984). The combined 
evidence indicates that the bivalent fibrinogen molecule 
bridges GP IIb/IIIa molecules on adjacent platelets in a 
ca2+-dependent manner. 
A number of studies using platelets from patients with 
Glanzmann's Thrombasthenia provide convincing evidence that 
GPIIb/IIIa is the major receptor for adhesive proteins. 
Their membranes have a marked deficiency in their capacity 
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to bind fibrinogen (Bennet and Vilaire, 1979), fibronectin 
(Ginsberg et al, 1983) and von Willebrand factor (Ruggeri et 
al, 1982) . 
2. The Vitronectin Receptor (CD51/CD61) 
In comparison to glycoprotein IIb/IIIa, this is a minor 
integrin on platelets. The alpha subunit (CD51) forms a 
ca2+-independent complex with the beta subunit (CD61), which 
is identical to GPIIIa (Lam et al, 1989). The receptor is 
known to bind the R3D-containing adhesive proteins 
vitronectin, fibronectin, vWf (Cheresh et al, 1987) and 
thrombospondin (Lawler and Hynes, 1989). This does not 
require platelet activation. 
All the adhesive proteins mentioned above, including 
fibrinogen, have been shown to contain the critical RGDS 
sequence (Rouslahti and Pierschbacher, 1987) . Significant 
identity of the amino acid sequences between members of this 
group have been found, as deduced from cDNA sequences. The 
RGD recognition specificity in the binding of ligands has 
been demonstrated for all three members of the Integrin 
superfamily. Members of the cytoadhesin family, particularly 
GPIIb/IIIa, exhibits high affinity for RGD (Pytela et al, 
1986). The VLA family has the same recognition specificity, 
but their affinity is less than that of the cytoadhesins 
(Ginsberg et al, 1987). 
THE NON-INTEGRIN GLYCOPROTEIN RECEPTORS 
1. Glycoprotein Ib (CD42b/CD42c) 
This glycoprotein together with GPIX and GPV, are members of 
the leucine-rich receptor family. Members include a variety 
of proteins with no apparent functional similarity, but 
share a common structural motif, composed of a leucine-rich, 
24-amino acid consensus sequence (Takahashi et al, 1985). 
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GPib consists of two disulphide-linked polypeptide chains, 
Ib alpha (CD42b) with a molecular weight of 143kDa, and Ib 
beta (CD42c) with a molecular weight of 22kDa, both of which 
are transmembrane proteins. Crossed immunoelectrophoresis of 
Triton-solubilized platelets with anti-glycocalicin antisera 
produces two peaks: glycoprotein Ib and a faster migrating 
peak, glycocalicin, a ca2+ -dependent protease degradation 
product of GPib (Solum et al, 1980). Studies using 
proteolytic enzymes have yielded important information on 
the structure of the alpha chain (Pepper and Jamieson, 1969; 
Berndt and Caen, 1984). ca2+-dependent protease cleavage 
splits off glycocalicin, with a molecular weight of 140kDa, 
leaving a residue which is linked to the beta chain. Trypsin 
cleaves glycocalicin to yield a highly glycosylated macro-
glycopeptide (118kDa), leaving a sugar-poor tail with a 
molecular weight of 45kDa, which is the platelet receptor 
for von Willebrand factor and thrombin. 
The role of GPib in the von Willebrand factor-dependent 
adhesion of platelets to exposed vascular endothelium was 
clearly demonstrated. (Meyer and Baumgartner, 1983). Its 
role as a receptor for thrombin remains controversial, as 
reviewed by Greco and Jamieson (1991). Studies have provided 
evidence of a high affinity pathway for thrombin-induced 
platelet activation which is GPib-dependent, and which is 
immunologically distinct from another GPib-independent 
system (Yamamoto et al, 1991). The monoclonal antibody TM60, 
directed against the thrombin-binding domain of GPib only 
inhibited this process by 50%, indicating the existence of a 
separate GPib-independent system. This is supported by the 
previous finding that platelets from which the thrombin-
binding portion domain was removed from the membranes with 
the use of Serratia marcescens protease, continue to be 
activated by alpha-thrombin, but required a four-fold 
increase in the concentration (Harmon and Jamieson, 1988). 
Recently, a thrombin receptor has been cloned which is 
probably the key component of the GPib-independent system, 
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interacting synergistically with the GPib receptor to 




of the seven-transmembrane domain family, with the 
LDPR41 ;s42 FLLRN at the amino-terminal exodomain. 
cleaves the Arg41;ser42 peptide bond, to unmask a 
new terminus beginning with the sequence SFLLRN. The later 
work of this group demonstrated that once unmasked, it is 
able to bind to the receptor, to effect its activation, thus 
functioning as a tethered intramolecular peptide ligand 
{Chen et al, 1994) 
GPib is highly complexed to a low molecular weight {22kDa) 
glycoprotein, GPIX. These, together with another 
glycoprotein, GPV {82kDa), are absent in the Bernard-Soulier 
syndrome (Berndt et al, 1983). This is a hereditary bleeding 
disorder characterized by a prolonged bleeding time, and 
thrombocytopenia with abnormal and large platelets. 
2. Glycoprotein IX (CD42a) 
This has a molecular weight of 22kDa, and is tightly but not 
covalently linked to GPib (complex: CD42), appearing as an 
elongated dumbbell-shaped complex. A large globular domain 
is inserted in the plasma membrane, with a smaller globule 
external to the membrane (Fox et al, 1988) The complex is 
co-immunoprecipitated by antiplatelet, quinidine-dependent 
antibodies {Chong et al, 1983). This accounts for the 
thrombocytopenia that some patients develop whilst on 
quinine or quinidine therapy. The platelets of patients with 
the Bernard-Soulier syndrome fail to react with 
quinine/quinidine drug-dependent antibodies (Kunicki et al, 
1978), providing evidence that the complex is the receptor 
for this antibody. 
This complex also binds 
unstimulated platelets to 
vessels. They stop, then 
vWf, allowing the adhesion of 
the subendothelium of damaged 
anchor the platelet to the 
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subendothelium under the high shear conditions within the 
microcirculation. 
3. Glycoprotein V 
This membrane component (MW 
enzymatic activity of thrombin. 
demonstrated that it was the 
surface protein hydrolysed by 
82kDa) is a substrate of 
Berndt and Phillips (1981) 
only detectable membrane 
thrombin, which preceded 
platelet aggregation. However, subsequent studies have 
demonstrated thrombin-induced platelet activation despite 
its prior removal by chymotrypsin (McGowan and Detwiler, 
1986), or pretreatment with antibodies to GPV which prevents 
its cleavage by thrombin (Bienz et al, 1986). This 
glycoprotein is also genetically absent from platelets of 
patients with the Bernard-Soulier syndrome (Berndt et al 
1983). 
4. Glycoprotein IV (CD36) 
This is a single chain structure with a molecular weight of 
88kDa, which has been identified on the membranes of 
platelets (Tandon et al, 1989a) . With the use of 
monospecif ic antibodies, aggregation and adhesion studies, 
it has been found to mediate the early stages of recognition 
and attachment to collagen (Tandon et al 1989b). The 
adhesion step, when examined in the micro-titre assay, was 
shown to be inhibited by Fab fragments of monospecific 
polyclonal anti-GPIV antibodies. These studies also 
suggested a second GPIV-independent mechanism for subsequent 
anchorage of the platelets to the collagen. As indicated 
above, the GPia-IIa complex is also involved in platelet 
spreading on collagen (Santoro 1986), with specificity to 
Type I and Type III collagen (Kunicki et al, 1988) 
the anti-GPIV antibodies 
interaction of platelets 
have 
with 




(Asch et al, 1987), an adhesive protein contained within 
platelets, required for their irreversible aggregation. 
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s. The Selectins: GMP 140 (CD62P) 
These comprise a family of cell surface receptors with an 
amino-terminal lectin-like domain, an adjacent epidermal 
growth factor-like domain, and multiple short consensus 
repeat units in tandem, homologous to the complement 
proteins. These receptors have a transmembrane component and 
a short cytoplasmic tail (Johnson et al, 1989) . GMP 140, 
also called PADGEM or CD62P is a single polypeptide of 
140,000MW which hae been identified as a constituent of the 
alpha granule membranes of platelets (Stenberg et al, 1985). 
It is minimally expressed in the resting state, but appears 
on activation and alpha granule secretion (Hsu-Lin et al, 
1984). It is considered to be a substrate for the binding of 
a wide variety of leucocytes, mediating their interaction 
with platelets in the cellular reaction to inflammation and 
haemorrhage (Johnson et al, 1989). 
6. The Immunoglobulin Gene superfamily 
This group is composed of subfamilies of glycoproteins 
involved mainly in cellular recognition and share the 
homology unit. Two members have been identified on the 
membranes of platelets: The HLA class I molecules and PECAM-
1 (CD31) a 130kDa glycoprotein (Newman et al 1990), with 
immunoglobulin domains similar to those of the cell adhesion 
molecule (CAM) subfamily, and thus likely to be involved in 
cellular interactions (Williams and Barclay, 1988) 
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LAMININ 
This is a major component throughout the basement membrane 
(Timpl et al, 1979), where it, together with type IV 
collagen, constitutes the major components, in association 
with proteoglycans and other glycoproteins like fibronectin, 
von Willebrand factor and thrombospondin. For experimental 
use, laminin is extracted from Engelbreth-Holm-Swarm (EHS) 
sarcomas grown in lathyritic mice, which produces abundant 
amounts of basement membranes. 
It is a glycoprotein having both a structural and a 
biologically active role (Timpl et al, 1979; Engel et al, 
1981; Rao et al, 1983), with a molecular weight of about 
1,000kDa in the unreduced state, and produces two components 
of molecular weight 200kDa and 400kDa under reducing 
conditions. It consists of three large polypeptide chains 
designated Bl (215kDa), B2 (205kDa) and A (400kDa) (Cooper 
et al, 1981). By means of many inter- and intra-chain 
disulphide bonds, these components form a cross shape in the 
natural state of the molecule, with a long arm (75nm.) and 
three short arms ( 3 0nm.) as seen in rotatory- shadowing 
images (Engel et al, 1981) (Plate 1). 
The four ends of the cross shape are globular, consisting of 
mainly carbohydrate. The intersection is protease resistant, 
containing numerous disulphide bonds, and is the binding 
site for the receptor of malignant and other cells. A single 
polypeptide called nidogen forms a stable complex with 
laminin, and the two are invariably associated within 
tissues. Nidogen was isolated from extracts of EHS tumour 
(Timpl et al 1983), and later shown to be a single 
polypeptide, dumbbell-shaped, with a molecular weight of 
150kDa (Paulsson et al 1986). One molecule binds through one 
of its globular domains to the centre of the intersection of 
the polypeptide chains. The biologic significance of this 
association is unknown (Martin and Timpl, 1987). 
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The complex of the two molecules in their natural state is 
seen in Plate 1, and a schematic model of the association is 
illustrated in Plate 2. 
Plate 1. In vitro laminin structure. 
Rotary-shadowing images of laminin from mouse EHS 
tumour(top) sea urchin embryo culture(third from top) rat 
Schwannoma cell culture (bottom) and of particles of the 
laminin-nidogen complex from EHS tumour(second). The 
probable position of the noncovalently attached, dumbbell-
shaped nidogen is indicated with arrows. (From Martin and 
Timpl, 1987). 
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A model of the laminin-nidogen complex showing protease 
fragments identified by Arabic numbers and the location of 
some biological activities. (From Martin and Timpl, 1987). 
Recent computer analysis of cDNA clones have established the 
amino acid sequence of the multidomain structure of the Bl 
chain (Sasaki et al, 1987). The N-terminal domains, VI and 
IV have a low cysteine content and forms the globular 
structures. Domain V has five cysteine-rich segments of 
about 50 amino acids, separated by gaps, whereas domain III 
has eight and contains the important sequence YIGSR that 
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supports cell att.achment, chemotaxis, and binding to the 
67kDa receptor of tumour cells (Graf et al, 1987) . The C-
terminal domains II and I have an alpha-helical structure. 
The B2 chain has a similar structure. The Ae, Ble, and B2e 
chains of laminin have since been fully sequenced (Sasaki et 
al, 1988) . The intersection of the three chains, is kept 
intact by disulphide bonds. They then run together, in 
parallel, to form the rod-iike segment of the long arm. The 
carboxyl terminus of the A chain forms the large globule at 
the end of the long arm. A schematic model of the 
arrangement of the three chains is illustrated in Plate 3. 
Binding to laminin elicits specific responses, causing 
secretory cells to become polarized (Hadley et al, 1985) , 
those of neural or l gin to extend axon-like processes (Baron 
van Evercooren et '.~l, 1982), and others to migrate (McCarthy 
et al, 1983). In cultures growth is strongly enhanced, with 
survival and differentiation facilitated ( Kleinman et al, 
1985) . The long a:cm binds heparin and stimulates neuri te 
outgrowth (Engvall et al, 1986) , whilst the globular end 
regions of the short arms promote cell spreading, bind to 
plasma membrane s~lphatides and to Type IV collagen (Rao et 
al, 1982) . 
On consideration of its wide range of biological activity, 
the finding that t~mour cells are rich in specific receptors 
for this unique glycoprotein (Terranova et al, 1983) 
suggests that these properties are active in the promotion 
of neoplastic growth and metastasis. 
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} Neurite Outgrowth 
} Heparin Binding 
Arrangement of the A, Bl and B2 chains in the laminin 
molecule. (From Martin and Timpl, 1987). 
LAMININ RECEPTORS 
Liotta has reviewed the work produced in his laboratory in 
isolating binding sites for laminin on the membranes of 
breast carcinoma cells (1986). The latter had a density of 
up to 100,000 molecules, are specific and of high affinity. 
Laminin-affinity column separation yielded a 67kDa peptide 
containing intrachain disulphide bonds, with an isoelectric 
pH of 5.2. Identical isolates were eluted from murine 
fibrosarcoma cells by Malinoff and Wicha ( 1983) and from 
murine muscle by Lesot et al (1983). Monoclonal antibodies 
15 
to the receptors recognize the corresponding component of a 
breast carcinoma membrane extract. Recent work by Wewer et 
al (1986) has detailed its amino acid sequence, deduced from 
molecular cloning studies. Receptor m-RNA was shown to be 
1,700 bases long. A schematic model showing the various 
residues of the the Bl chain of the laminin molecule 
recognized by the 67kDa receptor (Graf et al, 1987) , is 
shown in Plate 4. 
Plate 4. Model of chain molecular arran ement. 
PEPTIDES: 7 6 
H2N 








Schematic model of the laminin Bl chain. The Roman 
numerals designate the structural domains as derived from 
computer analysis of the deduced amino sequence. The 
Arabic numbers designate the locations of synthetic 
peptides. The peptides and their respective residue 
numbers in laminin are: peptide 1, residues 1593-1611; 2, 
residues 1509-1529; 3, residues 1395-1416; 4, residues 
1363-1383; 5, residues 960-978; 6, residues 615-634; 7, 
residues 364-385; 11, residues 925-933; 12, residues 903-
912. (From Graf et al, 1987). 
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A cysteine-rich residue of the B1 chain which contains the 
amino acids sequence: cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg at 
positions 925 to 933 is the cognate site for the 67kDa 
receptor. Functional aspects of these receptors on 
metastatic capacity was demonstrated by Barsky et al (1984b) 
using a murine model. Treatment of the cells with the 
receptor binding fragment of the laminin molecule, markedly 
inhibited or abolished metastases in a non-toxic fashion. 
PRIOR STUDIES ON THE PLATELET LAMININ RECEPTOR 
Using laminin-coated petri-dishes, Ill et al ( 1984) 
demonstrated adhesion of resting radio-labelled platelets. 
No evidence of release or aggregation was found and the 
cells remained rounded when examined by electron microscopy. 
These findings were in contradistinction to those with 
binding to fibronectin where they developed a flattened-out 
appearance, and the release of radio-labelled serotonin when 
bound to collagen. 
A constant fraction of the suspension was found to adhere to 
laminin when the unbound platelets were transferred to a 
second set of similarly prepared dishes. This indicated that 
it was not merely a sub-population that was binding. The 
adhesion was inhibited in the presence of anti-laminin 
antibodies but not by the RGDS peptide. 
Later adhesion studies using a similar approach was carried 
out on micro-titre plates by Sonnenberg et al (1988). They 
showed it to be supported by magnesium- as well as 
manganese- and cobalt-ions but not by calcium-, zinc- or 
copper-ions. Monoclonal antibodies to VLA-6 were shown to 
inhibit binding to laminin while the adhesion to plates 
coated with fibrinogen, fibronectin or collagen remained 
unaffected. It was thus concluded that the specific VLA-6 
receptor is distinct from the well established 67kDa 
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receptor on human breast carcinoma cells (Terranova et al, 
1983) . As mentioned above, these cells recognise the Cys-
Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg peptide of the Bl chain of 
the molecule. The authors claim that this peptide did not 
inhibit platelet adhesion in their model. The data from 
which they drew this conclusion unfortunately was not 
presented. 
Subsequent work by the same group using ligand affinity 
chromatography with the ES fragment of the long arm of 
laminin bound to the affinity column, isolated a complex of 
two polypeptides of 140 and llOkDa from radiolabelled 
platelet lysates. The complex was identified as VLA-6 by 
immunoprecipitation with specific antibodies to the alpha-6 
and beta-1 components (Sonnenberg et al, 1991). However, 
when the Pl laminin fragment, derived from the short arm was 
linked to the Sepharose column, the alphaII/beta3 
(GPIIb/IIIa) platelet integrin (which did not bind to the E8 
affinity column) was eluted, and no VLA-6 was evident. 
The binding of platelet lysates to columns to which the 
complete laminin molecule was linked, as was used in the 
present study, was not examined. 
18 
I CHARACTERIZATION OF PLATELET ADHESION TO LAMININ 
A. DEVELOPMENT OF A MICRO-TITRE ASSAY FOR MEASURING 
PLATELET-LAMININ INTERACTION 
INTRODUCTION 
A model was developed to study adhesion under varied 
conditions, whereby radio-labelled platelets were allowed to 
attach to the surface of micro-titre wells coated with 
laminin. The unattached cells were aspirated off and the 
remainder lysed with SDS. Adhesion was then calculated by 
measuring the amount of radio-label in the lysate. 
OPTIMIZATION OF THE MICRO-TITRE ASSAY 
Conditions were standardized, including: 
- the coating of the surface; 
- the selection of a suitable concentration of platelets; 
- the duration of incubation; 
- the optimal cation concentration for the suspension 
buffer; and 
- the demonstration of the· specificity of the interaction 
with the use of anti-laminin antibodies. 
Preparation of laminin-coated surface 
Flat bottomed microwell plates with high binding capacity 
(Nunc-Immuno plate, Maxisorp, 6mm diameter, Nunc, Denmark) 
were used to obtain a solid phase. The wells were coated by 
incubation with 50ul of a solution of laminin, (whole 







at room temperature 
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Preparation of platelet suspension 
Whole blood was obtained from volunteers, anticoagulated 
with CPD-Al at a ratio of 6:1 of blood to CPD-Al. Platelet-
rich plasma (PRP) was obtained by low speed centrifugation 
at 800xg for 10 minutes at 22°. PGE1 (Sigma Chemical Co., 
St. Louis, Mo.) at a concentration of lug/5ml was added to 
the PRP, the pH adjusted to 6.5 with citric acid. The cells 
were then sedimented by centrifugation at 1, 800xg for 10 
minutes, resuspended and washed twice in citrate wash buffer 
(5.5mM dextrose; 120mM NaCl; 4.26mM NaH2P04; 7.46mM Na2HP04; 
4.77mM trisodium citrate; 2.35mM citric acid, with 0.35% BSA 
at pH 6.5). Following resuspension in buffer A (5.0mM tris; 
5.5mM glucose; 150mM NaCl; 2.0mM MgC1 2 ) containing 0.5% BSA 
at pH 7.4 at a concentration of 1x109 per ml as determined 
by counting in a Coulter counter (Coulter Electronics, 
Hialeah, FL), they were labelled with Na 2 [
51crJ04 (50uCi/ml) 
(Amersham Corporation, IL - 250mCi/mg) by incubation at room 
temperature for 1 hour in buffer A. Finally, the labelled 
preparation was washed and resuspended in buffer A at a 
concentration of 5xl08/ml 
Assay of platelet adhesion 
The excess laminin was aspirated from the wells and 250ul of 
tris saline buffer A with o. 5% BSA at pH 7. 4 was added to 
each well for 30 minutes to block unoccupied sites on the 
bottom of the wells. The blocking buffer was aspirated off, 
50ul of the labelled suspension was then added in 
triplicate, and incubated at room temperature without 
rocking. After 60 minutes, the wells were aspirated and then 
washed twice with buffer A to remove the free cells. 
Adhesion was determined by lyzing the adherent population, 
using lOOul of 2% sodium dodecylsulphate (SDS) in water for 
30 minutes. The lysate from each well was individually 
collected and the 51cr content determined in a gamma counter 
(Autogamma 5000 series, Packard Instruments, IL). 
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1. LAMININ CONCENTRATION 
Aim: 
To define surface conditions for optimal and consistent 
adhesion. 
Methods: 
A range of concentrations from 40-320ug/ml in buffer A 
(without BSA) was prepared. 50ul of each was applied to the 
micro-titre wells in triplicate, to provide a range of 2ug-
16ug/well. The plates were then left at room temperature 
until they were needed. 
After a radio-labelled platelet suspension of 5xl08/ml was 
prepared, the excess laminin solution was then aspirated and 
the wells blocked with buffer A. 50ul of the platelet 
suspension was added to each well in triplicate. After 60 
minutes the excess cells were aspirated off and those 
adherent lysed with SDS. The radioactivity of each lysate 
was then determined as described above. The 51cr content of 
the lysates was determined with a mean blank value derived 
from uncoated wells, which was subtracted from the mean of 
the triplicate experimental values. 
Results and comment: 
The results indicate that there is an increase in adhesion 
as the concentration of laminin increases, as shown in 
Fig .1. 
The increase was rapid up to a concentration of 2ug/well 
(40ug/ml) but with a more gradual linear rise thereafter, 
appearing to reach a steady state. At the concentration 
selected for future assays, 8ug/well, there was a mean 
adhesion of 35xl05/ml (SE= 1). 
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Fi .1. 
0 2 4 8 12 15 
LAMININ CONCENTRATION - ug/well 
Number of platelets bound to various concentrations of 
laminin. Each point represents the mean value of three 
studies, each done in triplicate, using the platelets of 
the same donor on different days, plus/minus the Standard 
Error as indicated. 
These findings are similar to those of Ill et al (1984), who 
used laminin-coated petri dishes and a platelet 
concentration of 2x10 8;m1. Again a linear relationship with 
increasing laminin was demonstrated, up to a concentration 
of 30ug/ml. They used 30-40ug/ml for the solid phase in 
subsequent experiments. 
The tailing off of the increase in binding occurred at a 
lower laminin concentration in the study of Sonnenberg et al 
(1988). Greiner micro-titre plates were used, with a 
platelet concentration of 1x108/ml. The increase in binding 
was rapid up to a concentration of lOug/ml, slowing between 
lOug/ml and 2 Oug/ml and very 1 i ttle increase thereafter. 
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They used 20ug/ml in their adhesion studies. No detail of 
the well geometry ( flat or round bottomed) is provided, 
which may account for the this difference in the pattern of 
adhesion. 
Conclusion: 
Adhesion showed minor variation for laminin concentrations 
above 40ug/ml. A concentration of 160ug/ml (Bug/well) for 
the solid phase was thus considered satisfactory for optimal 
adhesion in all subsequent experiments. 
2. PLATELET CONCENTRATION 
Aim: 
To establish a suitable suspension for the study of variable 
degrees of adhesion. 
Methods: 
The micro-titre wells were coated with Bug/well of laminin 
and left at room temperature until needed. 
Whole blood was drawn into CPD-Al, PRP was prepared, and the 
cells labelled as described. Labelled concentrates ranging 
from 1x10 6/ml to 1x109/ml were prepared. 
The wells were aspirated to remove the excess coating 
solution. Buffer A was added to block uncovered sites on the 
surface for 30 minutes and then aspirated. 50ul of each cell 
concentration was applied in triplicate, providing a range 
of 5x105 to 500x105;well. Binding was allowed for 60 
minutes, after which the unbound cells were aspirated. 
The plates were washed twice with buffer to remove unbound 
cells and those adherent were then lysed with sos, their 
number calculated from the 51cr content of each well. The 
51cr content of 50ul of each concentration was equated with 
the total number of cells added. The number adherent was 
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calculated from the mean 51cr value at each concentration, 
as a proportion of the 51cr content of the platelets added. 
Results and comment: 
The adhesion increased, with a steep rise starting at 
1x108/ml. These values are shown in Fig.2. 
At a concentration of sx10 8/ml the mean adhesion was 47.23 
x10 5 /ml (SE = 2. 41). This point is noted to fall on the 
rapidly rising part of the curve. It is thus reasonable that 
any experimental condition that promotes or inhibits 
adhesion will cause well defined changes in the assay. 
Fi .2.: Platelet concentration. 
0 5 25 50 250 500 
CONG . OF PLATELETS ADDED X 10000 
Number of platelets bound (x10 5 ) with increasing 
concentrations of platelet suspension (x10 5/ml) added. 
Each point represents the mean value of three studies, 
each done in triplicate, using the same donor on different 
days, plus/minus the Standard Error as indicated. 
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Conclusion: 
The platelet concentration of 5xl0 8/ml is suitable for 
examining variable adhesion and all subsequent studies were 
standardised accordingly. 
3. DURATION OF INCUBATION OF PLATELET SUSPENSION WITH 
LAMININ 
Aim: 
To determine the duration of cell interaction with the 
laminin solid-phase to allow for optimal adhesion. 
Methods: 
The micro-titre wells were coated with 8ug/well of laminin 
and blocked with buffer A at room temperature until needed. 
Whole blood was drawn into CPD-Al, PRP was prepared, the 
platelets were labelled as described. 
The wells were aspirated to remove the excess buffer A and 
50ul of the suspension at a concentration of 5x108 /ml was 
applied in triplicate. The cells were allowed to bind for 
periods varying from 2-60 minutes, after which those unbound 
were aspirated. 
The plates were washed twice with buffer A to remove unbound 
cells and the bound fraction lysed with SDS. The number of 
adhered platelets were then calculated from the 51cr content 
of each well. The 51cr content of the 50ul of the suspension 
was measured as the total number of platelets added. The 
number adhered was calculated from the mean of the three 
51cr values of the lysates as a proportion of the 51cr 
content added. 
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Results and comment: 
Adhesion increased rapidly with increasing duration of the 
incubation time, up to 60 minutes, after which there was a 
minimal increase up to 90 minutes as seen in Fig.3. 
A reproducible lag phase in the first 5-10 minutes was 
noted. 
. 
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INCUBATION TIME - MINUTES 
Adhesion of platelets as a percentage of platelets added 
and incubated with laminin solid-phase for varying periods 
of time. Each point represents the mean of four studies, 
plus/minus the Standard Deviations as shown. 
conclusion: 
Optimal adhesion occurs at an i ncubation time of 60 minutes. 
This time was used for all subsequent studies. 
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4. CATION REQUIREMENT 
Introduction: 
Divalent cations are known to have an important influence on 
adhesion. Their removal by means of EDTA prevented platelet 
interaction with the non-collagen matrix of glomerular 
basement membranes (Huang and Benditt, 1978). Removal of 
ca2+ and Mg2+ from the suspending medium also abolished the 
ADP-mediated binding of fibrinogen to the GPIIb/IIIa 
platelet receptor (Mustard at al, 1978). 
Early studies by Hovig ( 1964) on the adhesion of rabbit 
platelets to collagen were confirmed in later studies using 
human platelets (Cowan et al, 1981). These investigators 
used a collagen-Sepharose column formed by covalently 
linking collagen to cyanogen bromide-activated Sepharose, 
and demonstrated increased adhesion in the presence of lrnM 
Mg2+. lrnM ca2+ did not support adhesion. With the use of 
Type I collagen coupled to plastic slides, Shadle and 
Barondes (1982) demonstrated an absolute dependence of 
adhesion on Mg2+, with ca2+ having an inhibitory effect. 0.5 
to 3rnM of Ca 2+ inhibited binding in the presence of lrnM 
Mg2+. lrnM EGTA inhibited adhesion by about 90%, which was 
overcome by increasing Mg2+ concentrations. A similar effect 
of the strong chelator EGTA was demonstrated by Cazenave et 
al ( 1979) . 4. 5rnM EGTA inhibited adhesion to the collagen 
coated surface to less than 10% of the control values. 
It is thus evident from the marked inhibition of adhesion in 
the presence of EGTA, that it is the process is dependent on 
divalent cations. Al though most studies have examined the 
effects of ca 2+ and Mg2+, others also have an influence. 
This was studied by Sonnenberg et al (1988), who showed it 
to be poor in the presence of the chelator EDTA, supported 
by magnesium-, manganese- and cobalt-ions, but inhibited in 
the presence of calcium-, zinc- and copper-ions. 
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Aim: 
To determine the influence of the two principal cations, 
ca2+ and Mg2+, in order to select an optimal concentration 
for the assay. 
Methods: 
The micro-wells were coated with laminin at a concentration 
of 8ug/well at room temperature. Whole blood was drawn into 
CPD-Al and PRP was prepared. 
The platelets were then labelled, washed and resuspended in 
Mg2+-free buffer A. The resuspension buffer was supplemented 
with increasing concentrations of Mg2+ ranging from O to 
2mM. In a second set of preparations, the buffers with an 
identical range of Mg2+ were supplemented with O, O. 5, 1, 
and 2mM ca2+ to provide an equimolar solution. A third set 
was prepared with identical concentrations of ca 2+ without 
Mg2+. All platelet concentrations were adjusted to sx108;m1. 
The excess coating solution was aspirated off and the wells 
were then blocked using buffer A without Mg2+ until they 
were ready for use. The wells were then aspirated to remove 
the blocking buffer, platelets from each suspension was 
added to the wells in triplicate, and the adhesion assay was 
then carried out as described above. Adhesion was expressed 
in terms of the 51cr content of the lysate from each well as 
a percentage of that in soul which was added. 
Results and comment: 
No adhesion occurred in the absence of divalent cations. It 
was strongly supported by Mg2+ at o. 5 mmol without any 
calcium (mean= 11.87%, SE =0.62). Further increases in the 
Mg2+ concentrations produced smaller increments, appearing 
to reach a steady state at 2.0mM (mean= 15.63%, SE= 0.7). 

















concentrations a fixed proportion of platelets were bound, 
with means of 9.63% (SE= 0.37), 9.6% (SE= 0.27) and 9.7% 
(SE= 0.4) for the 0.5, 1 and 2rnM equimolar concentrations 
respectively. The reason for this phenomenon is not clear, 
but may suggest competition at a cation binding site of the 
receptor. These results are shown in Fig.4. 
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CATION CONCENTRATION - rri1 
Platelet adhesion as a percentage of control in the 
presence of varying concentrations of cations present in 
the platelet suspension buffer. Top: Magnesium-ions. 
Bottom: Equimolar concentrations of magnesium- and 
calcium-ions. Each point represents the mean value of 
three studies, each done in triplicate, using the same 




Platelet adhesion to laminin is supported by magnesium- but 
strongly inhibited by calcium-ions. These results are 
consistent with those of Sonnenberg et al (1988) and mirror 
the conditions required for binding to collagen (Shadle and 
Barondes, 1982) and for fibronectin binding to platelets 
stimulated by thrombin (Plow et al, 1985). A calcium-free 
magnesium-ion concentration of 2rnM was considered as 
suitable for all subsequent adhesion assays 
5. SPECIFICITY 
Introduction: 
Initial studies by Ill et al (1984) demonstrated the 
specificity of platelet adhesion to laminin-coated petri 
dishes with the use of polyspecific IgG. Pre-incubation of 
the coated surface with the antibody produced inhibition of 
platelet binding. These findings were confirmed by 
Sonnenberg et al (1988). In both these studies though, the 
complete IgG antibody molecule was used. Binding to laminin 
of the solid phase by means of the two Fab portions of the 
molecule would leave the Fe portion free. As platelets 
possess membrane receptors for the latter, (Karas et al, 
1982), binding via this mechanism could interfere with the 
demonstration of specific inhibition. In the present study 
this possibility was avoided with the use of Fab fragments, 
thus retaining laminin recognition but without the this 
aberration. 
Aim: 
To demonstrate the specificity of platelet adhesion to 
laminin, by blocking the antigenic sites on the laminin of 
the solid phase with the use of anti-laminin Fab, using 
control IgG Fab fragments to exclude non-specific binding. 
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Methods: 
Fab fragments were prepared according to the methods 
obtained with the kit instructions of the manufacturer 
(Pierce Chemical Co. Rockford IL) from whom the immobilized 
papa in and protein A was obtained. O. 5 ml of immobilized 
papain (pre-washed in buffer) was added to 10mg IgG rabbit 
antibody directed at mouse laminin (Collaborative Research, 
Bedford Mass.) in 1. O ml freshly made 20mM NaH2P04, 20mM 
cysteine-HCl, lOmM EDTA-Na buffer at pH 6.2. This was 
incubated for 5 hours at 37° with rocking. 3.0ml lOmM Tris-
HCl at pH 7.5 was added, mixed and centrifuged. The 
supernatant was applied to a 
column equilibrated with lOmM 
5ml immobilized protein A 
Tris-HCl, pH 7.5 and the 
column was washed with 5ml of the same buffer, collecting 
the eluate. 
Fab fragments (non-immune) were produced from 
chromatographically purified rabbit IgG (Cooper Biomedical 
Malvern, PA) using identical methods, to serve as controls. 
The micro-titre wells were coated with 8ug/well of laminin 
until needed. Whole blood was drawn into CPD-Al, PRP was 
prepared and labelled as described. 
Increasing concentrations ranging 5-40ug/well (100-800ug/ml) 
of both the anti-laminin and the non-immune Fab fragments 
were prepared. 
The coated wells were blocked with buffer A for 30 minutes 
and then aspirated free of excess buffer A. 50ul of the Fab 
preparations were added in triplicate. This was allowed to 
incubate for 30 minutes at room temperature. The wells were 
then aspirated free of excess antibody, 2. 5X10 7 labelled 
cells were added to each well and adhesion assayed in the 
standard way. Adhesion was expressed as a percentage of that 
occurring without the presence of Fab fragments. 
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Results and comment: 
Adhesion was inhibited by 89% at an anti-laminin Fab 
concentration of 5ug/well, (mean adhesion was 10. 97%, SE = 
2. 03) • Complete inhibition was found at higher 
concentrations, as seen in Fig.5. 
The Fab fragments of the control IgG Fab were without effect 
up to a concentration of 40ug/well. A non-specific effect of 
the anti-laminin antibodies was excluded in this way. 
of assa. 
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ANTIBODY CONCENTRATION - ug/well 
Platelet binding following incubation of the laminin-
coated micro-wells with increasing concentrations of Fab 
fragments of anti-laminin IgG antibodies, expressed as a 
percentage of the total binding of platelets to antibody-
free wells (bottom), with Fab fragments of an irrelevant 
antibody serving as controls (top). Each point represents 
the mean value of three studies, each done in triplicate, 
using the same donor on different days, plus/minus the 
Standard Error as indicated. 
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Conclusion: 
The adhesion to laminin is mediated by specific membrane 
components of platelets. 
6. DISTRIBUTION OF PLATELET ADHESION IN NORMAL VOLUNTEERS 
Aim: 
To document the normal range of adhesion in the model, in 
order to establish its suitability for the study in normal 
randomly selected volunteers. 
Methods: 
Randomly selected healthy volunteers, on no medication 
within two weeks of the donation, were requested to donate 
blood samples for the platelet-laminin adhesion study, after 
being informed of its research nature. The percentage of 
platelets from a 5x108;m1 suspension that were bound in the 
assay carried out as described above was analysed for 32 
subjects, 21 male and 11 female. The number of cells bound 
was expressed as a percentage of that added to each well. 
Results and comment~ 
The percentage of adhesion ranged from 7.7-21% with a mean 
of 14.85, median of 14.65, and a standard deviation of 2.73 
for the whole group. The distribution curve is thus 
unimodel, slightly skewed to the right, with a narrow 
variation about the mean. Adhesion ranged from 9.6-21% (mean 
of 15.49) for males and 7.7-17.1% (mean of 13.64) for 
females. These results are shown in Fig.6. 
Conclusion: 
These results were normally distributed, with acceptable 
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% ADHESION 
Distribution of the adhesion of the platelets of 32 normal 
volunteers, 21 males and 11 females, as a percentage of 
the platelets added. Each value represents the mean of 
triplicate readings. 
THE BINDING CHARACTERISTICS OF THE PLATELET LAMININ RECEPTOR 
- A SUMMARY 
There exists a specific receptor for laminin on the 
membranes of human blood platelets, as demonstrated with the 
use of cognate antibodies. The specificity demonstrated in 
previous reports (Ill et al, 1984, Sonnenberg et al, 1988), 
was based on the use of the complete polyspecif ic 
immunoglobulin. Since the latter could interfere wi th the 
demonstration of laminin-specific inhibition, a modification 
was introduced to exclude such a non-specific effect. The 
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results of the present study, confirms the specificity of 
the process with the use of anti-laminin Fab fragments. 
The binding has distinctive characteristics. It is sensitive 
to the divalent cation concentration of the prevalent medium 
and platelets do not adhere in their absence, as shown with 
the use of EDTA by Sonnenberg et al (1988). These authors 
also show that the adhesion is supported by magnesium-, 
manganese- and cobalt-ions but not by calcium-, zinc- and 
copper-ions. These observations were extended in the present 
study by demonstrating a 38% inhibition of adhesion when 
platelets were suspended in a 2mM equimolar mixture of ca2+ 
and Mg2+ in the buffer as compared with the adhesion in the 
presence of 2.0mM Mg2+ alone. 
The validity of the model developed is rendered in its 
documented consistency in the measurement of adhesion. The 
platelets of the population of volunteers used in the 
present study shows a normal distribution pattern of 
adhesion, with a narrow range of variability. This allowed 
for the investigation of the effects of platelet membrane 
modification by platelet activation, enzyme proteolysis, 
antibody binding and adhesive protein interaction. 
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B. EFFECTS OF PLATELET ACTIVATION 
Platelet adhesion was studied with and without stimulation 
using two important agonists, ADP and thrombin. 
1. ADP ACTIVATION 
Introduction: 
When exposed to this 
fibrinogen, platelets 
aggregate. The latter 
calcium-linked complex 
nucleotide, in the presence 
undergo shape change and 
protein is known to bind to 





Leung, 1982), and stimulation leads to the exposure of these 
specific ca2+-dependent binding sites (Gogstad et al, 1982), 
that enhance this phenomenon. Radiolabelling shows this 
reaction to be minimal when examined in the resting state 
(Hawiger et al, 1980). However, this increased four- to 
five-fold with 4. 5uM of the agonist, the binding can be 
saturated and is of high affinity. In parallel, ultra-
structure showed transformation from a resting discoid shape 
to spherical forms, protrusion of several pseudopods and the 
lumens of the surface connected cannalicular system became 
distended. These characteristics have subsequently been 
confirmed in other studies (Marguerie et al, 1979; Bennett 
and Vilaire, 1979). 
Aims: 
To demonstrate the effects of activation by ADP on platelet 
adhesion to laminin. In view of the ca 2+-dependence of 
fibrinogen binding after such stimulation, the presence of 
this divalent cation was also studied to clarify its role. 
Methods: 
The micro-titre wells were coated with 8ug/well of laminin 
and left at room temperature until they were needed. 
36 
Previously described conditions ( Bennett and Vilaire 1979) 
were used in which plasma-free platelets were isolated 
through a Sepharose gel column, and involved: 
A: Blood was drawn into CPD-Al and PRP prepared and 
labelled. 
B: 60mls of 2B Sepharose (Pharmaseal Laboratories, 
Glendale Calif.) were degassed under negative suction for 30 
minutes and poured into a 50ml plastic syringe to a volume 
of 40mls. lOOmls (2.5 times the column volume) of buffer A 
was used to equilibrate the column, which was sealed until 
required. 3mls of the platelet suspension were applied to 
the column. 
C: Platelets filtered through the gel with constant 
cycling of buffer A. In this way the heavier platelets were 
eluted ahead of the fibrinogen-rich plasma. 1ml fractions 
with the highest opacity (containing the highest platelet 
concentrations) were pooled and counted. 
The preparation was then tested to ensure that it was free 
of fibrinogen-rich plasma, so that the binding sites could 
be activated without causing aggregation (Bennett and 
Vilaire, 1979). A negative aggregatory response to lOuM ADP 
stimulation was documented in a Payton dual channel 
aggregometer ( Payton Associates Inc, Buffalo, M) using a 
total volume of 400ul, containing 300ul of 0,5Xl08/ml 
platelets. A positive control sample of PRP aggregated 
normally, showing that there was no defective response to 
ADP. 
Buffer A was added to the isolated platelets to achieve a 
final concentration of 5Xl08/ml for each ADP concentration 
tested. The coated wells were aspirated free of excess 
laminin solution and then blocked with buffer A for 30 
minutes. Preparations of platelets in buffer A alone and 
with lmM calcium chloride were warmed to 37° in a water 
bath. The cells were then stimulated by adding lOuM ADP 
(Sigma Chemical Co., St. Louis, Mo) for 3 minutes. After 
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removal of excess buffer A, 50ul of each preparation was 
applied to the coated wells. 
The adhesion assay was then performed in the standard way 
(described in Section A - Development of a micro-titre assay 
for measuring platelet-laminin interaction, Page 19) . The 
results following on ADP stimulation with and without ca2+ 
were expressed as a percentage of that of unstimulated and 
ca2+-free controls. 
Results and discussion: 
There was no increase in the adhesion of the ADP-stimulated 
platelets, with a mean of 101.67% (SE = 0.23), which 
decreased to a mean of 88% with a wider variation (SE = 
16.74) in the presence of lmM cacl 2 , as shown in Table 1. 
ADP(% of control) ADP with ca++(% of control) 
101. 8 74.7 
101. 4 82.5 
101. 8 106.8 
Mean: 101.6 88 
Standard error: 0.23 16.74 
Table 1. Adhesion following platelet activation with ADP 
Activation of gel-filtered platelets with lOuM ADP without 
(first column) and with (second column) lmM ca2+. Values are 
expressed as a percentage of unstimulated controls with the 
mean and Standard Error of three studies, each done in 
triplicate, using the same donor on different days 
A similar unenhanced response to ADP is found 
of thrombospondin to platelets, increasing 
126% (Wolff et al, 1986). In the case 
in the binding 
only to about 
of fibronectin 
binding, even an increase to 3 times the level of controls 
was considered as unenhanced (Plow and Ginsberg . 1981). 
These results are in sharp contrast to the effect of ADP on 
fibrinogen binding, which increased rapidly, 8-fold over the 
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binding of unstimulated platelets (Bennett and Vilaire, 
1979) . 
However, caution should be exercised in interpretation of a 
negative response to ADP, as the critical period of maximal 
exposure of the binding site could have been missed. As seen 
in the case of fibrinogen, although specific binding 
increases at a constant rate for 30 minutes after activation 
(Marguerie et al, 1979), maximal enhancement has been shown 
to be transient (Mustard et al, 1978). When added after ADP 
stimulation, binding was less avid than when fibrinogen was 
added before stimulation. In the present study the platelets 
were added to the coated plates immediately after 3 minutes 
of ADP stimulation, 
Conclusion: 
Platelet adhesion to laminin is not induced by their prior 
stimulation with ADP. The presence of ca2+ during this 
reaction inhibited this phenomenon, thereby duplicating and 
so confirming its effect on unstimulated washed platelets as 
found in the initial optimisation studies (Page 26). 
2. THROMBIN ACTIVATION 
Introduction: 
This potent agonist binds to membrane GPib with high 
affinity and concurrently activates GPib-independent systems 
(Yamamato et al, 1981). An important thrombin receptor 
system has recently been identified (Vu et al, 1991), which 
functions as a tethered intramolecular ligand, activated by 
the proteolytic action of thrombin which frees it to mediate 
platelet stimulation (Chen et al, 1994). 
This leads to the enhancement of binding of macromolecular 
adhesive glycoproteins by GPIIb/IIIa (Coller, 1986). This is 
associated with a conformational change of the platelet 




(A) Platelets are activated, resulting in a shape change 
from discoid to round; the development of filopodia and 
pseudopodia (Reorganized actin and myosin) 
(B) Platelets aggregate when the tips of these extensions 
link to the GPIIb/IIIa of the membranes of adjacent 
platelets. The latter receptors, in their activated 
state, bind fibrin and to the adhesive glycoproteins of 
the subendothelial matrix (Tuszynski et al, 1985). 
(C) The aggregate contracts to form a plug. 
Aims: 
To demonstrate the effect of platelet activation by alpha-
thrombin on the adhesion to laminin. The results would 




Each micro-titre wells was coated with 8ug of laminin at 
room temperature until they were needed. Labelled platelets 
were prepared in the conventional way ( See page 19) , but 
using citrate wash buffer and buffer A containing EGTA (2mM} 
and PGE1 (lug/ml) in order to ensure that aggregation is 
prevented when thrombin was added. Aliquots for each 
thrombin concentration were prepared to achieve a final 
concentration of sx108 . 
The coated wells were then aspirated free of excess laminin 
solution and blocked with buffer A for 30 minutes. 
Human alpha-thrombin, produced in Jamieson's laboratory 
according to the methods of Fenton et al (1977), was added 
to each platelet sample to achieve concentrations ranging 
from 0-2units/ml and incubated for 5 minutes. Hirudin (1000 
units/mg protein, isolated from the leech (Pentapharm Ltd, 
Basel Switzerland) was then added to the preparation at 
equimolar concentrations to thrombin and the platelets were 
then washed once with EGTA-free citrate. 
The excess blocking buffer was aspirated from the wells and 
the activated platelets were then added in triplicate. 
Adherence was then assayed in the standard way, that 
following on thrombin stimulation expressed as a percentage 
of that of controls. 
Results and discussion: 
No effect occurred at low thrombin concentrations, but 
adhesion decreased to a mean of 76.4% (SE = 5.02} at 
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Fig.7. Adhesion following platelet activation with 
increasing concentrations of alpha-thrombin. 
2 
Each point represents the mean plus/minus the Standard 
Error of three studies, each done in triplicate, using the 
same donor on different days. 
The reason for the decreased adhesion seen after treatment 
with thrombin is unknown. Activation has been noted to 
induce conformational changes in glycoproteins GPib, GPIX 
and GPIIb/IIIa of the platelet membrane {Michelson and 
Barnard, 1987). A similar change of the receptor site for 
laminin could alter its binding capacity. Alternatively, 
thrombin-mediated proteolysis could modify the cognate 
receptor and so modulate its function. There also remains 
the possibility that thrombin had induced release of 
platelet constituents which could interfere with engagement 
with the ligand. The inhibitory effect of anti-fibrinogen 
antibodies as defined by aggregometry and phase contrast 
microscopy, was not associated with the release reaction as 
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measured by 14c-serotonin labelling (Tollefsen and Majerus 
1975). Release of fibrinogen contained within the alpha 
granules was unabated, became bound to the GPIIb/IIIa 
receptor and caused aggregation - this after all surrounding 
fibrinogen was inactivated by anti-fibrinogen Fab· As will 
be demonstrated in later studies, increasing concentrations 
of fibrinogen caused a progressive and marked decrease in 
platelet adhesion to laminin. It is conceivable that, 
although aggregation was inhibited with the use of EGTA and 
PGE 1 , release of endogenous protein following on activation 
could interfere with laminin binding. However, the wash step 
after thrombin stimulation rules out such a mechanism in 
this study. 
Conclusions: 
The adhesion of platelets to laminin is not enhanced by 
their activation with thrombin. 
SUMMARY OF PLATELET ACTIVATION STUDIES 
Enhanced binding following on platelet activation has been 
demonstrated for fibrinogen (Bennett and Vilaire, 1979, 
Hawiger et al, 1980), fibronectin (Plow and Ginsberg, 1981), 
and von Willebrand factor (Fujimoto et al, 1982, Ruggeri et 
al, 1983) . In the present study, ADP stimulation did not 
increase the adhesion of platelets to laminin. There was an 
inhibitory effect of thrombin stimulation on this event, 
which decreased to 7 6. 4 % in the presence of 2 uni ts/ml of 
alpha-thrombin. This reduction was unexpected and its cause 
remains speculative as discussed above. 
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C - ROLE OF KNOWN PLATELET GLYCOPROTEINS 
Three approaches were used to examine the role of known 
platelet glycoproteins. This phenomenon was defined firstly 
by adhesion following their experimental removal with 
proteolytic enzymes, secondly with the use of specific 
antibodies to established receptors of this class, and 
finally, in an experiment of nature with platelets obtained 
from two patients with deficiency of the GPIIb/IIIa 
receptor. 
EFFECTS OF PLATELET MEMBRANE PROTEOLYSIS 
Separate characterization was undertaken after exposure to 
trypsin, chymotrypsin, and the metalloprotease derived from 
the microorganism, Serratia marcescens 
1. TRYPSIN 
Introduction: 
This powerful protease has been widely used to 
membrane components responsible for various 
functions, where it removes GPib and GPIIb, 




GPib (molecular weight of 140kDa) is the most sensitive 
component (Ganguly and Gould, 1979). Studies by Pepper and 
Jamieson (1969) and Okumura and Jamieson (1976), with 
cleavage of a 120kDa macroglycopeptide, found a residual 
tail with a molecular weight of 45kDa, which is the receptor 
for thrombin. Furthermore, treated platelets have decreased 
adherence to collagen ( Cazenave et al, 197 8) , indicating 
that the receptor had been cleaved from the membrane. 
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Aims: 
To demonstrate the effects of proteolysis with this enzyme 
on the adhesion of platelets to laminin, in order to explore 
firstly whether the mediators are trypsin-sensitive, and 
specifically the role of GPib which is sensitive to such 
treatment. 
Methods: 
Micro-titre plates were coated with laminin and left at room 
temperature until needed. 
Platelets were then prepared and labelled in the standard 
fashion, except where after the final wash, they were 
resuspended in buffer A without BSA. Aliquots were then 
treated with O. lmg/ml of trypsin ( Sigma Chemical Co. St 
Louis Mo) for varying periods ' ranging from Oto 60 minutes, 
washed and resuspended in buffer A to attain a final 
concentration of sx10 8 for each time point preparation. 
The laminin-coated wells were aspirated free of excess 
coating solution and blocked with buffer A. After 30 minutes 
this was decanted and 50ul of platelets from the untreated 
control and the various incubation-time preparations added 
in triplicate. Adhesion was then assayed in the conventional 
way (Page 19). The 51cr content of the lysate of adherent 
platelets from the control and each time point preparation 
was expressed as a percentage of that in soul added to each 
set of wells. The adhesion of untreated platelets (not 
subjected to trypsin) , was recorded as the 100% reference 
point. 
Results and discussion: 
As illustrated in Fig.8, adhesion decreased by 76% after 10 
minutes of exposure of the platelets to the protease. 
Thereafter the drop was slower, with the adhesion at 60 
minutes down to 7.27% (SE= 9.95). The protease effect was 
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Fig.a: Adhesion following on treatment of platelets with 
trypsin O.lmg/ml. 
Platelet adhesion as a percentage of controls following on 
proteolysis for various periods of time. Each point 
represents the mean value of three studies, each done in 
triplicate, using same donor on different days, plus/minus 
the Standard Error . 
conclusion: 
Laminin binding by platelets is mediated by a membrane 
component which is removed by trypsin proteolysis. Thus the 
sensitive portion of GPib and GPIIb may play a role, but the 




Platelets treated with this enzyme have decreased adhesion 
to collagen coated surfaces (Santoro and Cunningham, 1979). 
They do not demonstrate amine storage release, and are thus 
not activated by the proteolyis (Podolsak, 1977; Greenberg 
et al, 1979b) . Of note is that the PAS-staining material, 
presumably glycopeptides, recovered from the proteolysis is 
mainly the glycopeptide of GPI (Cazenave et al, 1979). Other 
studies have demonstrated a 45% removal of sialic acid 
(Okumura and Jamieson, 1976), as well as GPI, leaving only 
GPIV remaining (Greenberg et al, 1979a), with the result 
that they have a markedly reduced adhesion to collagen 
(Santoro and Cunningham, 1979). Confirmation was provided by 
Niewiarowski et al (1981), who also demonstrated a decreased 
aggregation response to ristocetin. 
Platelets so treated respond poorly to thrombin and ADP, but 
aggregated when fibrinogen was added, without prior 
activation by agonists (Greenberg et al, 1979a, 1979b) 
(untreated platelets require prior activation). This was 
confirmed by Niewiarowski et al (1981) with the use of 1251-
Fibrinogen. The conclusion was that chymotrypsin proteolysis 
removed glycoproteins which shield the binding site in the 
resting state, which are not decreased, as proven with 
monoclonal antibodies to GPIIb/IIIa (Peerschke et al, 1984, 
Niewiarowski et al, 1985) 
Tam et al (1980) studied the response of chymotrypsin-
treated platelets to thrombin, showing there was neither a 
decrease in the rate or extent of binding, al though there 
was a lag phase in the response. When hirudin was added 
during this phase, activation was abolished. This lead to 
the conclusion that the thrombin binding site was resistant 
to the proteolytic effect of chymotrypsin, but separate from 
the active post-binding receptor processing point generating 
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the response signal. It is the latter site which is 
sensitive to the protease effect of chymotrypsin. 
Aims: 
To observe the membrane proteolytic effects of chymotrypsin 
on platelet adhesion to laminin. Specifically, to explore 
the roles of components resistant to such treatment, the 
thrombin receptor, GPIIb/IIIa (the fibrinogen receptor), and 
GPIV, the receptor for collagen (Tandon et al 1989b) and 
thrombospondin (Asch et al, 1987). 
Methods: 
The micro-titre plates and platelet suspension were prepared 
identically to that described for trypsin proteolysis (see 
methods above). 
Aliquots of platelet were treated with O. lmg/ml of 
chymotrypsin (Sigma Chemical Co. St Louis Mo) for Oto 60 
minutes. Each of the time point preparations were then 
washed and resuspended in buffer A. 
The laminin-coated wells were aspirated free of excess 
laminin solution and blocked with buffer A. After 30 minutes 
this buffer was decanted and 50ul of platelets from the 
untreated control and the various incubation-time 
preparations were then added in triplicate. Adhesion was 
then assayed in the conventional way ( Page 19) . The 51cr 
content of the lysate of adherent platelets from the control 
and each time point preparation was expressed as a 
percentage of that in 50ul added to each set of wells. The 
adhesion of untreated platelets (not subjected to 
chymotrypsin), was recorded as the 100% reference point. 
Results and discussion: 
Chymotrypsin treatment effected a sharp decrease in 
adhesion, to a mean of 69% (SE= 2.99) within 10 minutes and 
this was followed by a slower reduction, to reach 37% (SE= 
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Fig.9: Effect of treatment of platelets with chymotrypsin 
O.lmg/ml. 
Platelet adhesion as a percentage of controls following on 
protease treatment for varying periods. Each point 
represents the mean value plus/minus the Standard Error of 
three studies, each done in triplicate, using the same 
donor on different days 
The experiment was repeated with the concentration of the 
chymotrypsin increased to O. 2mg/ml. A similar pattern was 
observed, the adhesion at 10 minutes dropping to 57 % (SE= 
11. 18) with a slower rate of fall thereafter, to reach 
values near to those obtained with O. lmg/ml trypsin - 16% 
(SE = 6.74) at 60 minutes. These results are shown in 
Fig.10, together with those following chymotrypsin O.lmg/ml 
and O.lmg/ml trypsin treatment for comparison. 
0 ·, o 
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Fig.lo. Effect of treatment of platelets with chymotrypsin 
O.lmg/ml, chymotrypsin o.2mg/ml and trypsin O.lmg/ml. 
Graphs of platelet adhesion as a percentage of controls 
after treatment for varying periods with Top: Chymotrypsin 
O.lmg/ml; Centre: Chymotrypsin 0.2mg/ml, means plus/minus 
Standard Error shown; Bottom: Trypsin O.lmg/ml. Each point 
represents the mean of three studies using platelets from 
the same donor on different days. 
Conclusion: 
The platelet membrane component responsible for adhesion to 
laminin is sensitive to the protease effect of chymotrypsin, 
which is similar to, though less rapid than with trypsin. 
From these results, GPIV (Greenberg et al, 1979a), the 
fibrinogen receptor GPIIb/IIIa (Greenberg et al, 1979b; 
Niewiarowski et al, 1985; Peerschke et al 1984) , and that 
for thrombin (Tam et al 1980), which remain intact on 
platelets treated this way have no role in the adhesion of 
platelets to laminin. 
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3. SERRATIA MARCESCENS METALLOPROTEASE 
Introduction: 
This enzyme has a selective effect on GPib, which has a 
molecular weight of 185kDa (Cooper et al, 1982), which is 
cleaved, with the release of a 165kDa glycopeptide. 
Platelets thus treated became unresponsive to von Willebrand 
factor and ristocetin-mediated aggregation and were 
desensitized in their response to thrombin. 
Aims: 
To demonstrate the effect of the Serratia marcescens-derived 
metalloprotease on the adhesion of platelets to laminin 
through its selective effect on GPib. 
Methods: 
The micro-titre plates and platelet suspensions were 
prepared identically to that for trypsin proteolysis (See 
above). 
Aliquots of platelets were then treated with O. 2mg/ml of 
Serratia protease obtained from Jamieson' s laboratory, for 
periods ranging from o to 60 minutes. Each of the 
preparations were then washed and resuspended in buffer A. 
The laminin-coated wells were aspirated free of excess 
laminin solution and blocked with buffer A. After 30 minutes 
this buffer was decanted and 50ul of platelets from the 
untreated control and the various incubation-time 
preparations were then added in triplicate. Adhesion was 
then assayed in the conventional way (Page 19). The 51cr 
content of the lysate of adherent platelets from the control 
and each time point preparation was expressed as a 
percentage of that in 50ul added to each set of wells. The 
adhesion of untreated platelets (not subjected to the 
metalloprotease), was recorded as the 100% reference point. 
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Results and discussion: 
Adhesion was not affected by the protease treatment, as seen 
in Table 2. 
Treatment time (minutes) 10 20 40 60 
Adhesion (% of control) 124.4 106.7 122.4 95.5 
110.1 109 120.2 105.6 
104.5 94.8 91. 6 94.2 
Mean: 113 103.5 111. 4 98.43 
Standard Error 10.26 7.62 17.18 6.24 
Table 2. Adhesion of platelets treated with o. 2mg/ml of 
Serratia marcescens protease for varying periods of time 
Each point represents the mean value of three studies, each 
done in triplicate, using the same donor on different days. 
Conclusion: 
The component of the platelet membrane responsible for the 
adhesion to laminin is not removed by the metalloprotease of 
Serratia marcescens. Because this enzyme selectively 
destroys the important adhesive glycoprotein, GPib (Cooper 




Monospecific polyclonal immunoglobulins against glycocalicin 
and GPIV were studied 
1. ANTI-GLYCOCALICIN 
Introduction: 
This antigen is a highly glycosylated fragment of 
glycoprotein Ib, rich in sialic acid and characterized by 
marked PAS staining. It is made up of a single polypeptide 
chain with a molecular weight of 150kDa and binds both 
thrombin and von Willebrand factor (Okumura and Jamieson 
(1976a, 1976b). 
Aim: 
To determine the effect of antibodies to glycocalicin on 
platelet adhesion to laminin. Thus by blocking the binding 
site on GPib, unaffected adhesion would provide support for 
the findings using proteolysis of GPib by the 
metalloprotease of Serratia marcescens, that it has no role. 
Methods: 
Micro-titre plates were coated with laminin at room 
temperature until needed. Platelets were then prepared and 
labelled as described (Page 19) and finally suspended in 
buffer A to attain a final concentration of sx108 for each 
concentration. 
Aliquots were incubated with increasing concentrations of 
Fab fragments of monospecific, polyclonal antibodies to 
glycocalicin ranging from 0-20ug/well (0-400ug/ml) for 30 
minutes at room temperature. The plates were decanted free 
of excess solution, buffer A added for 30 minutes and then 
removed, and platelets from each anti-glycocalicin Fab 
concentration preparation added in triplicate. Adhesion was 
then assayed in the conventional way (Page 19). The 
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adherence at each antibody concentration was expressed as a 
percentage of the adherence of controls. 
Results and discussion: 
There was 85% adhesion ( SE = 7. 2 6) at concentrations of 
anti-glycocalicin as high as 400ug/ml (20ug/well). These 
results are shown in Table 3. 
Concentration (ug/well) 2.5 5 10 20 
Adhesion (% of control) 100.2 101.7 106.6 78.4 
102 112.4 94.9 92.6 
117.4 93.7 91. 2 82.9 
Mean: 106.53 102.6 97.57 84.63 
Standard error: 9.45 9.38 8.04 7.26 
Table 3. Adhesion of platelets in the presence of varying 
concentrations of polyclonal monospecific anti-glycocalicin 
Fab 
Each point represents the mean value of three studies, each 
done in triplicate, using the same donor on different days. 
Conclusion: 
Since no inhibition occurred under these conditions, it can 
be assumed that GPib is in no way implicated, confirming the 
results of the studies using the metalloprotease of Serratia 
marcescens. 
2. ANTI-GLYCOPROTEIN IV 
Introduction: 
Physiologically GPIV is a single chain 88kDa glycoprotein. 
On isolation it inhibits the initial step in the adhesion of 
platelets to collagen (Tandon et al, 1989b) and also their 
interaction with thrombospondin (Asch et al, 1987). The 
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latter is an adhesion protein contained within platelets, 
required for their irreversible aggregation. 
Aim: 
To examine platelet adhesion after blocking the GPIV 
receptor with antibodies, in order to support the findings 
of the chymotrypsin proteolysis study (see above), that it 
has no integral role. 
Methods: 
The micro-titre plates and platelets were then prepared 
identically to the anti-glycocalicin study above. 
Aliquots of platelets were incubated with concentrations of 
Fab fragments of monospecific, polyclonal antibodies to GPIV 
ranging from 0-400ug/ml (0-20ug/well) for 30 minutes at room 
temperature. The plates were decanted free of excess laminin 
solution, blocked with buffer A which was drained after 30 
minutes and platelets from each anti-glycocalicin Fab 
concentration preparation added in triplicate. Adhesion was 
then assayed in the conventional way (Page 19). The adhesion 
at each concentration was expressed as a percentage of that 
in the absence of the antibodies. 
Results and discussion: 
Adhesion was 85% (SE= 18.58) at concentrations of anti-GPIV 
as high as 400ug/ml (20ug/well). These results are shown in 
Table 4. 
Conclusion: 
The failure of anti-GPIV antibodies 
excludes a role for this receptor 
platelets to laminin, confirming the 
chymotrypsin study 
to inhibit adhesion 
in the adhesion of 
conclusion of the 
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Concentration (ug/well) 2.5 5 10 20 
Adhesion (% of control) 94.3 86.5 74.1 63.2 
103.4 97.1 90.7 97.2 
97.1 91. 8 102.5 93.2 
Mean: 98.27 91.8 89.1 84.53 
Standard error: 4.66 5.3 14.27 18.58 
Table 4. Adhesion of platelets in the presence of varying 
concentrations of polyclonal monospecific anti-GPIV Fab 
Each point represents the mean value of three studies, each 
done in triplicate, using the same donor on different days. 
GLANZMANN 1 S THROMBASTHENIA 
Introduction: 
This autosomal recessive bleeding disorder is characterized 
by a prolonged bleeding time and absent or delayed clot 
retraction (Solum 1985). There is no aggregatory response to 
ADP, collagen, thrombin and adrenalin due to the absence of 
GPIIb/IIIa from their platelet membranes, including another 
GPIIIa component - the PLAl alloantigen. This is in contrast 
to other aspects of the platelet membrane structure and 
function which are intact, such as the von Willebrand factor 
systems. Thus they adhere normally to collagen fibres (Caen 
et al, 1966) and to exposed subendothelial tissue in flowing 
blood (Tschopp et al, 1974). 
Aim: 
To examine the adhesion of platelets from individuals with 
this disorder, which would provide conclusive information 
about the role of the missing receptor and verify the 
observation of the study using chymotrypsin proteolysis (see 
above) which negates such a role. 
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Methods: 
Micro-titre plates were coated with l aminin and blocked with 
buffer A until needed. Platelets from two blood samples as 
well as from a normal control were prepared and labelled in 
the conventional fashion (Page 19). 5x108/ml of each sample 
were added to the coated wells, and the adhesion assayed. 
That of the Glanzmann's platelets was expressed as a 
percentage of the normal control. 
Results and discussion: 
As seen from Fig.11, the platelets from both patients 
adhered normally, with values of 95 % and 90 % of the control. 
CONTROL PATIENT-A PATIENT-B 
Fig.11: Glanzmann 1 s Thrombasthenia 
Adhesion as a percentage of controls of the platelets of 
two patients with Glanzmann's Thrombasthenia, who have a 
congenital deficiency of the GPIIb/IIIa platelet membrane 
receptor. The values are the means of triplicate readings. 
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conclusion: 
The glycoprotein GPIIb/IIIa is conclusively ruled out as 
being the receptor for laminin on the platelet membrane. The 
findings using chymotrypsin proteolysis are confirmed. 
SUMMARY OF MEMBRANE GLYCOPROTEIN STUDIES 
Different kinetics govern the enzymatic cleavage of the 
laminin receptor from the membrane, which can be exploited 
in defining the mechanism of adhesion. A rapid proteolytic 
effect is found with trypsin, whereas with chymotrypsin this 
is slower and requires a higher concentration to achieve an 
equivalent effect. 
GPIV is not removed by chymotrypsin (Greenberg et al, 
1979a), thus the decreased adhesion after treatment excludes 
it as playing a role. The unaffected adhesion in the 
presence of antibodies to GPIV supports this conclusion. 
Similarly the receptors of GPib are not involved. Thrombin 
binding sites are not removed by trypsin (Pepper and 
Jamieson, 1969; Okumura and Jamieson, 1976) or chymotrypsin 
(Tam et al, 1980), and thus the decreased adhesion excludes 
this site. Also the Serratia marcescens metalloprotease 
removes the von Willebrand factor receptor of GPib (Cooper 
et al, 1982), but does not affect adhesion. Furthermore, 
antibodies to glycocalicin did not inhibit adhesion. 
GPIIIa remains intact after trypsin proteolysis (Greenberg 
et al 1979a), and thus the decreased adhesion excludes its 
involvement. The GPIIb/IIIa complex, the fibrinogen 
receptor, remains intact on trypsin and chymotrypsin treated 
platelets (Peerschke et al 1984; Niewiarowski et al, 1981, 
Niewiarowski et al, 1985), and is similarly excluded. 
Finally and conclusively, complex is excluded by the finding 
that platelets of individuals with Glanzmann's 
Thrombasthenia, who do not have this receptor on their 
membranes, adhere normally to laminin. 
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D - ROLE OF ADHESIVE PROTEINS 
Having defined the role of the key membrane components in 
the adhesion to laminin, this binding process was examined 
in relation to that for other plasma proteins. Fibrinogen, 
bound by GIIb/IIIa, von Willebrand factor, bound by GPib, 
and the peptide, RGDS, a structural component of many 
adhesive proteins which is recognised by a wide range of 
membrane receptors, were useful in this regard. 
1. FIBRINOGEN 
Introduction: 
The receptor for this protein is known to be the ca2+ -
dependent GPIIb/IIIa complex ( Bennett and Vilaire, 1979) . 
Extracellular binding is specific and 
stimulated platelets (Brinkhaus et al, 
by the abolition of aggregation with 
saturable on ADP-
1965), as confirmed 
the use of anti-
fibrinogen Fab (Tollefsen and Majerus, 1975). No intra-
platelet fibrinogen is released with ADP-induced 
aggregation, in contrast to the release with thrombin 
activation (Holmsen et al, 1969), allowing aggregation to 
proceed unabated in the presence of anti-fibrinogen 
antibodies. 
Binding of fibrinogen to the platelet in its resting state 
is non-specific and unsaturable up to levels greater than 
lOmg/ml, in contrast to that with ADP stimulation, which is 
specific and saturable at 0.2mg/ml (Peerschke et al 1980). 
Aim: 
To study the adhesion of platelets to laminin in the 
presence of fibrinogen. 
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Methods: 
The micro-titre plates and platelets were prepared in the 
conventional way (Page 18 and 19). 
Aliquots of platelets were incubated with increasing 
concentrations of fibrinogen up to 2mg/ml, for 30 minutes at 
room temperature. The coated micro-wells were blocked as 
described and platelets from each concentration preparation 
added in triplicate. Adhesion was then assayed (Page 19). 
The adherence at each fibrinogen concentration was expressed 
as a percentage of controls. 
Results and discussion: 
At low concentrations there was a rapid peak in adhesion, 
with a mean of 164% (SE = 23.9) at 0.25 mg/ml, dropping 
rapidly to 46% (SE= 19.55) at 1.0 mg/ml and at physiologic 
plasma levels of fibrinogen, 2.0 mg/ml, adhesion was totally 
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Fig.12: Interaction with fibrinogen 
Effect of incubation of platelet suspensions with 
increasing concentrations of fibrinogen (mg/ml) on the 
adhesion of platelets, expressed as a percentage of 
controls. Each point represents the mean value of three 
studies, each done in triplicate, using the same donor on 
different days, plus/minus the Standard Error 
It would thus appear that non-specific occupation of the 
GPIIb/IIIa receptor by fibrinogen altered membrane binding. 
Thus lower concentrations appeared to expose the site and 
enhances adhesion, but as this rises into the physiologic 
range blocking occurs. Parallels exist in the binding of 
thrombin-stimulated platelets to thrombospondin (Wolff et 
a l , 1986) and fibronectin binding to platelets (Plow et al 
1985) in the presence of this protein. The latter authors 
considered the following as mechanisms for this phenomenon: 
1. Fibrinogen may spatially interfere with fibronectin 
association. 
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2. Down-regulation of the binding site for fibronectin. 
3. Higher affinity for the site which is responsible for 
fibronectin binding. 
4. Interaction with 
interference. 




context, it is postulated that inhibition of 
interaction with adhesive proteins by fibrinogen 
a role in preventing platelet adhesion in the 
disease-free state. Such a role was also suggested for 
platelets in the activated state (Pietu et al 1984). ADP- or 
thrombin-activated binding of von Willebrand factor was 
inhibited by 80% in the presence of physiological 
concentrations of fibrinogen. This was confirmed in a later 
study which also demonstrated normal binding of radio-
labelled von Willebrand factor to activated platelets in the 
plasma of patients with congenital afibrinogenaemia and in 
plasma heat-treated to inactivate all the plasma fibrinogen 
(Schullek et al 1984). These plasmas became inhibitory for 
von Willebrand factor binding when fibrinogen was added at a 
concentration above lmg/ml. 
Conclusions: 















2. VON WILLEBRAND FACTOR 
Introduction: 
As reviewed by Ruggeri and Zimmerman {1985), this is a 
multimeric glycoprotein of endothelial origin, and 
circulates as a noncovalent complex with the procoagulant 
protein, Factor VIII, where it contributes to about 95% of 
the mass of the complex. 
Physiologically, in coagulation it serves to protect Factor 
VIII from degradation. Congenitally decreased levels or 
abnormal forms are found in von Willebrand's disease where 
it contributes to the haemostatic defect by allowing rapid 
degradation of Factor VIII. A second physiological 
consequence of the quantitative and qualitative defect in 
the molecule is the abnormal adhesion of platelets at high 
shear rates within the circulation. Under these conditions 
von Willebrand factor bound to GPib on the membrane, 
attaches to exposed subendothelial tissues, thus allowing 
the platelets to adhere. In its absence, this function is 
lost. 
GPib binding of von Willebrand factor is induced by the 
antibiotic ristocetin (Kao et al 1979). This cannot occur in 
patients with the Bernard Soulier syndrome with a congenital 
absence of GPib (Jenkins et al, 1976), as also found with 
the use of monoclonal antibodies {Coller et al, 1983). 
Binding of von Willebrand factor to platelets activated by 
agonists is mediated by a different mechanism. Ruggeri et al 
{1983) used platelets from normals, patients with the 
Bernard Soulier syndrome (absent GPib) and Glanzmann's 
Thrombasthenia (absent GPIIb/IIIa) to demonstrate that 
GPIIb/IIIa is the receptor for von Willebrand factor on the 
stimulated platelet, and that this binding was totally 
independent of the ristocetin-induced GPib mechanism. 
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Aim: 
To determine the effect of the presence of von Willebrand 
factor on the adhesion of platelets to laminin 
Methods: 
The micro-titre plates and platelets were prepared in the 
conventional way (Page 18 and 19) 
Aliquots of platelets were incubated with increasing 
concentrations of purified von Willebrand factor, up to 2 
units/ml for 30 minutes at 37°. The plates were blocked, the 
excess decanted as described ( Page 19) and platelets from 
each concentration preparation added in triplicate. Adhesion 
was then assayed in the standard way. The adherence at each 
von Willebrand factor concentration was expressed as a 
percentage of controls. 
Results and discussion: 
At physiological levels of 1 unit/ml, there was 38% 
inhibition, increasing to 66% at 2 units/ml, as shown in 
Fig.13. 










membrane site for laminin binding. As previously reported 
(Ruggeri et al 1983), non-specific binding of Radio-labelled 
von Willebrand factor in the resting state increase linearly 
as the concentration of the von Willebrand factor increases, 
to a level 10-3 5% of that bound to stimulated platelets. 
Excess'cold' von Willebrand factor was able to displace the 
specifically bound labelled von Willebrand factor, which 
decreased down to 30-50% of the maximal binding. 
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0 0 .5 
vWF CONC . units/ml 
Fig.13: Effect of von Willebrand Factor 
Effect of incubation of platelets with increasing 
concentrations of von Willebrand factor on adhesion, 
expressed as a percentage of controls. Each point 
represents the mean value of two studies, each done in 
triplicate, using the same donor on different days, 
plus/minus the Standard Error (SE). 
Conclusion: 
2 
von Willebrand factor inhibits the adhesion of platelets to 
laminin. 
3 THE ADHESION PEPTIDE - RGDS 
Introduction: 
A wide range of receptors with significant identity of their 
amino acid sequences as deduced from cDNA sequences, have 
recognition specificity for a critical amino acid sequence: 
arginine (R) glycine (G) aspartic acid (D), and 
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sometimes - serine (S). The adhesion proteins fibrinogen, 
fibronectin, von Willebrand Factor and vitronectin have all 
been shown to contain this sequence. 
RGD(S) recognition in the binding of ligands has been 
demonstrated for all members of the integrin superfamily. 
Members of the cytoadhesin family, particularly GPIIb/IIIa, 
exhibits high affinity, critical for fibrinogen binding 
(Pytela et al, 1986). The leu-cam family recognizes a region 
of the complement protein CJ which contains the RGD amino 
acid sequence (Wright et al, 1987). The VLA family also has 
the recognition specificity for a wide range of adhesive 
proteins, but their affinity is less than that of the 
cytoadhesins (Ginsberg et al, 1987). 
Although previous studies have shown unaffected adhesion of 
platelets to laminin in the presence of RGDS up to a 
concentration of lmM ( Ill et al, 1984, Sonnenberg et al, 
1988), this is such an important peptide in cell binding of 
adhesive proteins, that it was still considered important to 
confirm this in the present model. 
Aim: 
To study the interaction of RGDS with platelet adhesion to 
laminin. This would provide information about the nature of 
the recognition site of the responsible platelet membrane 
component. 
Methods: 
The micro-titre plates and platelets were prepared in the 
conventional way (Page 18 and 19). 
Aliquots of platelets were incubated with increasing 
concentrations of RGDS (Peninsula Laboratories Inc. Belmont, 
CA) up to lmM/ml for 3 O minutes at room temperature. The 
plates were blocked, the excess decanted as described (Page 
19) and platelets from each RGDS concentration preparation 
were then added in triplicate. Adhesion was then assayed in 
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the standard way. The adherence at each RGDS concentration 
was expressed as a percentage of controls. 
Results and discussion: 
There was an initial drop in adhesion to a mean of 73% (SE= 
9.02) at a concentration of O.lrnM RGDS, with a slower rate 
of fall thereafter, to a level of 50% at lrnM. This is shown 
in Table 5. 
Concentration (mmol) 0.1 o.s 1.0 
Adhesion % of control 76.5 69.6 60.3 
79.2 65.6 49.6 
62.4 46.3 39.5 
Mean: 72.7 60.6 49.8 
Standard error: 9.02 12.57 10.4 
Tables. Adhesion in the presence of varying concentrations 
(mM/ml) of the RGDS peptide 
Means of triplicate readings of three studies, using the 
same donor on different days. 
Thus no specific inhibition of adhesion could be 
demonstrated. However, the constant fall observed, without 
reaching a plateau, suggests some inhibition of adhesion by 
RGDS at very high concentrations. However, as demonstrated 
by Ill et al ( 1984) , who found a similar gradual drop in 
adhesion, the rate of fall was no different from that found 
with an irrelevant peptide. This suggests a non-specific 
effect of RGDS. 
Conclusion: 
The molecular structure responsible for the adhesion to 
laminin does not specifically recognise the peptide RGDS, 
contrary to the findings in a wide range of adhesive 
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proteins bound by all members of the integrins, particularly 
the cytoadhesins. It is thus similar to that for 
thrombospondin (Asch et al 1987), even though the RGD 
sequence has been identified in the cloned thrombospondin 
message (Lawler and Hynes, 1989). Laminin may similarly be 
found to contain this sequence, but at a site separate from 
that responsible for ligand binding by the platelet 
membrane. 
SUMMARY OF ROLE OF ADHESIVE PROTEINS. 
It appears that fibrinogen and von Willebrand factor 
interfere with laminin membrane binding on platelets. What 
was not excluded at this stage was artifactual adsorption of 
these proteins onto the laminin surface, blocking 
interaction with the membrane recognition site. This 
possibility was examined by adhesion experiments in which 
the laminin coated micro-wells were pre-incubated with von 
Willebrand factor up to twice the physiological 
concentration ( 2 uni ts/ml) , and f ibrinogen up to 2 mg/ml, 
followed by washing of the wells with buffer A. Washed and 
labelled platelets were then added to the wells and adhesion 
assayed in the standard fashion. This produced no inhibition 
of adhesion of platelets, as seen in Fig.14, which rules out 
such a possibility. 
The most likely explanation is that this is a non-specific 
effect (Dr. Leon W Hoyer: personal communication). This was 
also considered as the mechanism of the inhibitory effect of 
fibrinogen on thrombospondin binding to thrombin-stimulated 
platelets (Wolff et al 1986). 
These facts, derived experimentally, extrapolate to 
physiologic regulation. Marked inhibition of binding of von 
Willebrand factor to ADP- or thrombin-stimulated platelets 
by physiological concentrations of fibrinogen was found 
(Pietu et al 1984). The latter authors considered the 
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likelihood that this interaction may play a role in 
maintaining blood platelets in the resting state within the 
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Fig.14: Effect of pre-incubation of the laminin-coated 
wells with fibrinogen and von Willebrand Factor 
2.00 
The wells were pre-incubated with increasing 
concentrations of fibrinogen (mg/ml) (bottom) and von 
Willebrand factor (units/ml) (top) and washed before 
determining platelet adhesion as a percentage of controls. 
Values are the means of triplicate readings. 
The platelet membrane component responsible for the adhesion 
to laminin does not appear to recognise the important RGDS 
peptide sequence. However, the model conditions could allow 
for underestimat i on of its role, as demonstrated in its 
recognition in the C3 complement molecule by leu-cam of 
neutrophils, only becoming evident when tested as part of a 
larger peptide (Wright et al 1987). This was not tested in 
the present study. 
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III ISOLATION OF THE PLATELET LAMININ RECEPTOR 
As there was no precedent for this work, the initial 
development was based on methods used to isolate laminin 
receptors from the membranes of human breast carcinoma cells 
(Barsky et al, 1984a). 
A. PREPARATION OF SOLUBILIZED PLATELET MEMBRANES: 
250 mls of platelet rich plasma were prepared by 
centrifugation of whole blood drawn in CPD-Al. 50ug of PGE1, 
2rnM benzamidine, lug leupeptin and 5rnM EGTA were added to 
prevent aggregation. 
After two washes with citrate buffer containing 0.35% BSA, 
pH 6.5, and one with citrate buffer pH 6.5 without albumin, 
they were resuspended in 5ml of 50rnM tris buffer containing 
5rnM EGTA, 2rnM phenylmethylsulphonyl fluoride and 50ug/ml 
leupeptin, at a platelet concentration of 2x10 9/ml. 
Following sonification at 4 ° (Bronson Soni fer, setting 7) 
using 5x 20-second pulses at 15-second intervals, providing 
a crude membrane preparation, the cell debris and unbroken 
platelets were removed by centrifugation at 10,000xg for 10 
minutes at 4°. 
The membrane fraction was recovered by centrifugation at 
100,oooxg for 90 minutes at 4° and dissolved in 2mls buffer 
A (without albumin), pH 7.4, containing 0.1% Triton XlOO and 
lOOug leupeptin with rotation for 2 hours at 4°. The 
insoluble material was removed by centrifugation at 
100,000xg for 30 minutes at 4°. 
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B. PREPARATION OF THE LAMININ-SEPHAROSE COLUMN: 
10mg of laminin (Collaborative Research, MA) was 
concentrated by centrifugation at 800rpm for 10 minutes 
using a PM-30 Amicon Centricon ultrafiltration apparatus. 
The volume was made up to lOOul and added to 1ml of a O.lM 
Na-bicarbonate, 0.5M NaCl buffer at pH 8.3. 
333mg of CNBr-activated Sepharose 4B (Sigma Chemical MO) was 
added to 50ml lmM HCl on ice, filtered and washed several 
times. The gel was then transferred to a small column 
(Econo-Column, Biorad). 
The laminin in bicarbonate-saline buffer was added to the 
gel, and rotated for 3 hours at room temperature. The 
laminin-gel was centrifuged at 2,000 rpm for 5 minutes and 
then blocked with 1ml of lM ethanolamine, pH 8 for 2 hours 
at room temperature. The coupled gel was then washed twice 
with the bicarbonate-saline buffer and then with buffer A 
(without albumin). 
C. BINDING OF SOLUBILIZED PLATELET MEMBRANES TO 
COLUMN: 
This preparation was washed twice with buffer A (without 
albumin) pH 7.4, and resuspended in a final volume of 40ul, 
which was added to the laminin-Sepharose column. 
After 18 hours of cycling at 4° at a flow rate of 20ml/hr, 
the column was washed several times with the same suspension 
buffer. Sequential elution was then carried out with a 
series of buffers, 3 column volumes each: Buffer A, buffer A 
with 0.1% Triton XlOO, buffer A with 0.1% Triton XlOO and lM 
NaCl, buffer A with o. 1% Tri ton XlOO and 5mM EGTA and 
finally with o. 2M glycine-HCl with o. 1% Tri ton XlOO at pH 
2.85. Each fraction was collected into tubes containing 75 
ul Tris ( lM/1) so as to raise the pH to 7. 6. 1ml of each 
fraction was then concentrated by ul trafil tration (Amicon 
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Centricon, PMJO apparatus) and centrifugation at 800rpm for 
10 minutes. 
D. ELECTROPHORESIS OF THE ELUATE: 
This was carried out on samples from each of the fractions 
of the sequential elution, solubilized in 1% sodium 
dodecylsulphate (SDS), in their non-reduced form in a 7% 
SDS-polyacrylamide gel, using tris.glycine buffer. 
Solubilized samples of the final eluate were similarly 
processed in both the nonreduced form and after exposure to 
2. 5% 2-mercaptoethanol, together with a control sample of 
human serum albumin which has a similar molecular weight, 
and high molecular weight standards (2000,000 Myosin: 
rabbit skeletal muscle; 116,250 Beta-galactosidase: E 
Coli; 97,400 Phosphorylase B: rabbit muscle; 66,200 
Bovine serum albumin; 45,000 - Ovalbumin: hen egg white; 
31,000 - Carbonic anhydrase: bovine; BioRad, Richmond Cal) 
on the same gel. 
Proteins on the gel were fixed with 12% trichloracetic acid, 
silver stained (Biorad) and the molecular weights determined 
by plotting against the curve generated from the standards. 
RESULTS: 
The sequential eluate revealed increasing purity of a single 
band of about 53kDa, becoming very dense in the final 
fraction with O. 2 mmol glycine-HCl containing o. 1% triton 
XlOO at pH 2.85, seen in Plate 5. 
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Plate 5. Membrane components from the sequential elution 
from the laminin-affinit column. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 MW 
53K~ ... .... ~ -
Lanes 1-3: Wash buffer A. Lanes 4-6: Buffer A with 0.1% 
Triton XlOO. Lanes 7-9: Buffer A with 0.1% Triton XlOO and 
lM NaCl. Lanes 10-12: Buffer A with 0.1% Triton XlOO and 
5mM EGTA. Lanes 13-15: 0.2M glycine-HCl with 0.1% Triton 
XlOO, pH 2.85. The platelet membrane fraction of molecular 
weight 53kDa of increasing density is seen 
The elution pattern was identical to that obtained during 
the isolation of the well characterized laminin receptor 
isolated from the membranes of human breast carcinoma cells 
(Liotta: personal communication). 
The final eluate revealed a single major band indicating 
about 95% purity, although some minor components were 
detectable, particularly in the reduced gel, as seen in 
Plate 6. 
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Plate 6. Platelet membrane laminin receptor. 
67 K __. 
53 K--+ 
--~-
-- ··•·· "'-40f.. , 
1 2 3 
7% SDS gel of the laminin receptor eluted with glycine 
HCL, 0.1% Triton XlOO, pH 2.85 buffer, in the non-reduced 
(MW 53kD) and reduced state ( 67kDa) , distinct from the 
human albumin control. 
The molecular weight of this component, 67kDa in the reduced 
state and 53kDa in the unreduced state, was identical with 
that previously reported for the laminin receptor of human 
carcinoma and murine f ibrosarcoma cells (Terranova et al, 
1983; Malinoff and Wicha, 1983). 
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E. BLOT IDENTIFICATION: 
Nitrocellulose membrane (Bio-Rad) was cut to fit a petri 
dish, soaked with tris buffered saline, pH 7. 5. and then 
dried for 5 minutes on filter paper. 
A concentrated sample (5ul) of the final eluate was applied 
to two of the quadrants marked on the membrane, with control 
samples of human albumin on the other two. Excess binding 
sites were blocked with Tween 20 (0.3%) in phosphate 
buffered saline (PBS), containing 2% BSA for 45 minutes 
using gentle agitation on a shaker platform. A 1:1,000 
dilution of laminin in PBS containing 2% BSA was added to 
the preparation (aspirated free of blocking buffer 
immediately prior to use), and incubated overnight at 4°. 
After several washes with PBS-Tween 20 containing 0.1% BSA, 
the buffer was aspirated off and a 1: 1,000 dilution of 
rabbit anti-laminin antibody (Collaborative Research, 
Bedford, MA) in PBS containing 0.1% BSA added and incubated 
for 3 hours at 4°. 
The paper was then washed several times with PBS-Tween 20 
containing 0.1% BSA. After the final wash buffer was 
aspirated off, peroxidase-conjugated goat anti-rabbit IgG 
(Bio-Rad Immun-Blot GAR-HRP) was added and incubated for 1 
hour at room temperature with gentle agitation. This was 
followed by several washings with PBS-Tween-BSA wash buffer, 
the final wash with tris buffered saline, pH 7.5. The 
proteins were identified using freshly prepared 4-chloro-1-
naphthol and hydrogen peroxide colour developing reagent 
(BioRad) . 
RESULTS: 
Blot identification of the concentrated sample of the final 
eluate on nitrocellulose paper demonstrated adherence of 
laminin to the eluted protein, with a negative reaction to 
human albumin which has a similar molecular weight, as seen 
in Plate 7. 
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The human platelet membrane component is identical to the 
well characterized laminin receptor from the membranes of 
human breast carcinoma cells, in elution pattern expression 
and molecular weights. It binds laminin in a specific way. 
A 67kDa laminin receptor on human platelets has thus been 
identified. This is the first time that such a receptor has 
been discovered on platelets. 
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IV. ADDITIONAL CONFIRMATION 





(Ordinas et al, 1992) 
Platelet incubation with 
antiserum to 67kDa receptor 
Laminin-Sepharose elution 
of cold/labelled membranes 
Immunoinhibition with anti-
bodies to 67kDa receptor 
Adhesion to laminin-derived 
peptides 
Blocking of membranes with 
laminin-derived peptides 
Membrane binding to peptide-
Sepharose columns 
(Tandon et al, 1991) 





on flow cytometry 





Recovery of 67kDa 
protein 
The possible physiologic relevance of the platelet laminin 
receptor to cellular interaction with the subendothelium in 
whole blood was supported in studies using abdominal aorta 
segments in the Baumgartner annular perfusion chamber. The 
evaluation was carried out according to the basic criteria 
described by Baumgartner (1973) with minor modification 
(Bastida et al, 1986). The segments were incubated with 
either PBS, Fab fragments of a rabbit anti-mouse laminin 
antibody (50ug/ ml) or a similar concentration of an 
irrelevant antibody. After perfusion with anticoagulated 
whole blood from normal healthy donors who had not taken any 
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drugs 1n the previous 10 days, they were rinsed and fixed 
with glutaraldehyde. Morphometric evaluation of embedded and 
stained specimens was then employed, using a manual optical 
picture analysis system (MOP 20 Kontron), connected to a 
computer with an automated recognition programme. 
Results and comment: 
Pre-incubation of the vessel segments 
antibody (Fab), led to reductions in 
with anti-laminin 
the total surface 
coverage, the percentage of spread platelets and the 
percentage of aggregates less than Sum in height (p<0.005). 
These findings are consistent with the interaction found in 
the laboratory and provides evidence of specific laminin 
recognition in the physiologic response of platelets to 
injury to vascular endothelium. This also provides support 
for the hypothesis of this thesis, relating to the 
facilitating role of this receptor in lodgement of platelet-
tumour emboli in vivo (see The Role of Platelets in 
Metastasis in next section). 
B. FLOW CYTOMETRY 
Washed platelets were incubated with polyclonal rabbit 
antiserum to the 67kDa laminin receptor isolated from human 
breast carcinoma tissue, with controls exposed to normal 
rabbit serum. Fluorescein isothiocyanate labelled goat anti-
rabbit IgG (Cooper Biomedical, Malvern PA) was used as the 
second antibody, and the signal measured with a flow 
fluorocytometer (EPICS Coulter Corporation, Hialeah, Fl). 
Results and comment: 
The antibody to the 67kDa laminin receptor produced an 
intense fluorescent signal as compared with normal IgG, 
indicating that about 99% of the platelets were labelled. 
Thus the surface location of the receptor is confirmed, 
which has strong affinity for laminin. 
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C. RECEPTOR ELUTION FROM LAMININ-SEPHAROSE COLUMN 
Affinity chromatography with columns prepared according to 
methods described in the present study (See Preparation of 
the laminin-Sepharose column) were used to monitor the 
binding of labelled and 'cold' platelet receptors. Crude 
membranes from one unit of 125r-labelled platelets were 
mixed with 20 units of unlabelled membranes, dissolved in 
Triton X-100 and applied to the column, which was washed 
with application buffer until the absorbance and 
radioactivity in the eluate had fallen to approximately 
baseline values. Stepwise elution was then initiated with 
collection of 4ml fractions and the pH adjusted to 7.6 with 
75ul of lM Tris. 
Results and comment: 
There was a rapid fall in the radioactivity with washing of 
the column with buffer. Subsequent elution demonstrated 
peaks with the following: 
- lM NaCl, followed by a drop back to the baseline; 
- Glycine/HCl containing Triton X-100 produced a major peak 
of strong absorbance which cleared the column of 
radioactivity, SDS added to the elution buffer produced no 
further peaks. 
In the eluates of unlabelled platelet membranes monitored by 
u-v absorption against Triton X-100 in the reference 
cuvette, glycine/HCl caused a major decrease in the 
absorption. These results are shown in Plate 8. 
SDS /PAGE of the glycine/HCl fraction concentrated by Amicon 
Centricon (PM30) filtration confirmed the elution of the 
67kDa (reduced) and 53kDa (unreduced) platelet membrane 
component. Protein blotting using a polyclonal antibody 
prepared against the 67kDa laminin receptor of human breast 
carcinoma confirmed their immunological identity. 
The elution pattern, molecular weights as well as the 
cognate binding of antibodies for platelet membranes is thus 
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reproducible and similar to that of breast cancer cell 
(Barsky et al, 1984b). 
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Elution peaks with radioactivity (a) and absorbance (b) 
obtained with lM NaCl(arrow 1), buffer containing 5mM EGTA 
(arrow 2), and finally 0.2M glycine/HCl containing 0.1% 
Triton X-100 (pH 2.85) (arrow 3). 
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D. IMMUNOINHIBITION WITH MONOCLONAL ANTIBODIES 
Immunoglobulins (3Dl and 6G4) raised against the LR-1 
peptide sequence in the 67kDa laminin receptor of malignant 
cells were incubated with platelets before they were added 
to the micro-titre plates in the adhesion assay. 
Results and comment: 
There was a 50-60% inhibition of adhesion while an 
irrelevant anti-Factor IX antibody was without effect (Plate 
9). This confirms the immunologic identity to the 67kDa 
receptor of breast carcinoma cells. Of significance, the 
immunoinhibition was not total, indicating the probable 
involvement of other platelet membrane receptor systems, and 
supports the working hypothesis of this thesis that both the 
VLA-6 (Sonnenberg et al, 1988) and the 67kDa receptor are 
required for optimal platelet adhesion to laminin. 
8 1 
Plate 9 Irnmunoinhibition of latelet adherence. 
IMMUNOINHIBITION OF PLATELET ADHESION TO LAMININ 
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ANTIBODY (.JL) 
Immunoinhibition using the standard micro-titre assay and 
culture supernatants containing IgM monoclonal antibodies. 
Bottom: 6G4 and Centre:3Dl, anti-bodies raised against the 
human tumour cell laminin receptor. Top: Negative control 
antibody (anti-human factor IX). The points shown are the 
averages of two determinations each carried out in 
triplicate. 
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E. PEPTIDE ADHESION STUDIES 
Two laminin-derived peptides, a pentapeptide, Tyr-Ile-Gly-
Ser-Arg and an octapeptide, Cys-Asp-Pro-Tyr-Ile-Gly-Ser-Arg-
NH2 as described by Graf et al (1987) in a range of 
concentrations (0.1-150ug) were applied to the micro-titre 
plates and dried overnight. An irrelevant peptide Gly-Ala-
Arg-Gly served as a negative control and 8ug laminin as the 
positive control. After blocking with albumin, the 51cr-
labelled platelet adhesion assay was carried out as 
described. 
Results and comment: 
These peptides, derived from the critical site of laminin to 
which the 67kDa breast cancer receptor binds, support 
adhesion (Plate 10). They are thus recognised by receptors 
on the platelet membranes. This provides evidence that the 
related structures have a similar affinity for this site of 
the laminin molecule. Of note is that the binding efficiency 
decreases with truncation of the proteins. 
In another study these peptides at a concentration of lmM, 
were pre-incubated with platelets for 30 minutes prior to 
adding to the laminin-coated plates in the adhesion assay. 







The partial blocking of the membrane site responsible for 
the adhesion by these peptides derived from the Bl short arm 
of the laminin molecule and specifically recognized by the 
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breast cancer membrane 67kDa receptor, suggests that the 
platelet membrane has similar recognition specificity. 


















1.00 10.00 100.00 
Peptide Concentration [uG/Well] 
Means of adhesion+/- SD for three separate experiments, 
each performed in triplicate. Top: Octapeptide. Centre: 
Pentapeptide. Bottom: Gly-Ala-Arg-Gly(negative control). 
The vertical bar shows binding to laminin(8ug/well) as a 
positive control. 
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F. LAMININ FRAGMENT SEPHAROSE COLUMN STUDIES 
The Cys-Asp-Pro-Tyr-I1e-Gly-Ser-Arg-NH2 peptide was linked 
to 2B-Sepharose, a Triton XlOO-solubilized platelet membrane 
preparation was cycled over the columns and the bound 
components eluted as described (see above). The glycine-HCl 
eluate fractions were concentrated with an Amicon Centricon 
(PM30) apparatus and studied with SDS-polyacrylamide gel 
electrophoresis. 
Results and comment: 
This revealed a dense band of the 67kDa (reduced) receptor. 
The immunologic identity this receptor with the 67kDa 
counterpart of human breast carcinoma cells was established 
by protein blotting using polyclonal antibodies. 
The avid binding of the 67kDa platelet membrane component to 
the Sepharose column to which the peptide derived from the 
Bl short arm of the laminin molecule was linked, confirms 
the specificity of the membrane binding site. As this 
peptide forms the essential part of the complementary domain 
critical for the recognition by the breast cancer membrane 
67kDa receptor (Graf et al, 1987), the identical molecular 
weights, and the immunological identity on protein blotting 
provides overwhelming evidence that the 67kDa platelet 
membrane component is a receptor for laminin. 
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V. CONCLUSIONS AND IMPLICATIONS. 
THE MICRO-TITRE ASSAY 
A micro-titre assay has 
adhesion of platelets to 
the basement membrane. 
reproducible, specific 
been developed to evaluate the 
laminin, a major glycoprotein of 
It is simple to set up, rapid, 
and economical in the use of 
reagents. From this baseline, a number of variables were 
investigated. 
Ill et al (1984) were the first to describe this phenomenon, 
using coated petri-dishes, but required large volumes of 
reagents. This was addressed by the assay developed by 
Sonnenberg et al (1988) who used Greiner micro-titre plates. 
The present assay was a modification of this, but used 
highly absorptive micro-titre plates (Maxisorp Nunc-Immuno, 
Nunc, Denmark), which allowed adequate and constant 
adhesion, thus facilitating the investigation of the 
membrane interactions in the adhesion process. 
Applying this approach, previous observations relating to 
the specific cation requirement have been extended. Ill et 
al (1984) used Dulbecco's modified Eagle's medium, which 
contains 1. 8mM Ca 2+ and O. 8mM Mg2+. A wide range of these 
cations were individually tested in the study of Sonnenberg 
et al ( 1988) , including Mg2+ which was shown to support 
adhesion and ca2+ which inhibits it. The present assay has 
demonstrated the increasing adhesion with increasing 
concentrations of Mg2+, where ca2+ was found to effectively 
stop the increase when above a concentration of 0.5mM. 
New information about the platelet membrane receptor for 
laminin is provided: 
First of all, its binding is not enhanced by prior 
platelet activation with the two powerful platelet agonists, 
ADP and thrombin. In fact, there is a drop in adhesion with 
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thrombin activation, due most likely to conformational 
change induced by its binding to the platelet membrane. It 
is also possible that the receptor site is interfered with 
through its proteolytic properties. 
- Secondly, it is removed by both trypsin and chymotrypsin, 
which rapidly decreases adhesion, but not by the Serratia 
marcescens metalloprotease which, although it removes 
glycoprotein Ib ( Cooper et al, 1982) , has no effect on 
adhesion, and so excludes the involvement of the latter 
glycoprotein. However, since GPIIIb is not removed by 
trypsin, and GPIV, the fibrinogen receptor (Greenberg et al, 
1979a) and the thrombin receptor (Tam et al 1980) is not 
affected by chymotrypsin, the decreased adhesion of 
platelets treated with these enzymes excludes their 
involvement in mediating the adhesion. 
- Thirdly, neither glycocalicin or GPIV could have any role, 
since adhesion was unaffected in the presence of antibodies 
to these adhesive receptors. 
- Fourthly and definitively, GPIIb/IIIa was discounted as 
having any participation in the process, as platelets from 
two individuals with Glanzmann' s Thrombasthenia, who lack 
this receptor, adhere normally. 
Finally, a fifth point currently of undetermined 
physiologic significance, is the marked inhibition of 
adhesion in the presence of the adhesive plasma proteins, 
fibrinogen and von Willebrand factor. 
Combining all the available data, it is possible to tabulate 
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THE PHYSIOLOGY OF THE 67kDA RECEPTOR FOR LAMININ ON PLATELET 
MEMBRANES 
More receptors for the many forms of laminin, and also in a 
wide variety of species, have been identified than actual 
active sites on the molecule (for recent review, see Mecham, 
1991). These include nonintegrins, a llOkDa protein, 
galactose-binding lectins, sulfatides, galactosyl-
transferase, and a variety of integrins. It is not clear why 
so many receptors for laminin exist. It is possible that 
multiple receptors on different cells can recognise the same 
active site, and integrin receptors can recognise multiple 
extracellular matrix components, even varying with different 
cell types (Kleinman et al, 1993). 
Recently an alternative site for the interaction between 
laminin and the 67kDa receptor was established by electron 
microscopy, using the rotatory shadowing technique (Cioce et 
al, 1993). The laminin receptor used was purified from human 
colon carcinoma metastases, and appeared as a globular 
structure with a diameter of 5. 2 +/- O. 8nm. The receptor 
specifically bound to laminin on its long arm, close to the 
intersection of th e long and short arms. Furthermore, the 
receptor bound only laminin fragments obtained from 
enzymatic digestion that retained a short piece of the long 
arm (chymotrypsin), and not to a pepsin digest (Pl fragment) 
which removed that part of the long arm. The binding site 
for the 67kDa receptor has thus been identified as a region 
on the long arm of laminin, close to the intersection of the 
four arms. 
Given the overwhe ].ming evidence in support of the 67kDa 
platelet membrane component being a receptor for laminin 
presented in this thesis, the conclusion must be drawn that 
it operates in a complementary system with the VLA-6 
integrin. 
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Antibody to the Ic (alpha) subunit of VLA-6 inhibits 
platelet adhesion to laminin (Sonnenberg et al 1988) which 
clearly establishes its role as a receptor for laminin. 
The central role of the isolated 67kDa receptor in specific 




Immunologic identity to 
cancer cell 67kDa receptor 
67kDa-specific platelet 
membrane function in adhesion 
Receptor specific for 67kDa 
cognate site on laminin 
Specific recognition of 
cognate site on laminin 
METHOD 
Protein blotting 
Protein blotting and flow 
cytometry: with anti-67kDa 
Decreased platelet adhesion 
with anti-67kDa. 
Inhibited platelet adhesion 
with peptide pre-incubation 
Cognate peptide affinity-
chromatography 
However, as shown earlier, monoclonal antibodies 3Dl and 6G4 
raised against the LR-1 peptide sequence of the 67kDa 
laminin receptor of breast carcinoma cells only cause a 50-
60% inhibition of adhesion in the micro-titre assay. This 
together with the observation of an initial lag phase in the 
first 10 minutes of the adhesion in the time course study 
(Study 3), suggests that other receptors for laminin must be 
present for optimal adhesion. 
A similar conclusion was drawn to account for the variation 
of receptors recovered when different laminin fragments were 
studied by affinity chromatography (Sonnenberg et al 1991). 
VLA-6 adheres to a f finity columns when platelet lysates are 
passed over them (Sonnenberg et al, 1991). These columns 
however, carried the E8 laminin fragment, with similar 
results for both murine and human laminin. When coupled with 
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the Pl murine laminin fragment, a different receptor, GPIIb-
alpha3 (GPIIb/IIIa) was recovered. The linkage of the intact 
laminin molecule, as has been used presently, was not 
studied in any of the isolation procedures, 
expected, the 67kDa receptor was not eluted. 
thus as 
In the present work, only the 67kDa receptor was recovered 
both when the intact laminin and the Bl peptide containing 


















The variant findings could be due to a number of factors: 
The importance of the particular laminin fragment attached 
to the affinity column in determining the receptor recovered 
in the eluate has been stressed in other cell systems. 
Gehl sen et al ( 1988) isolated an integrin receptor (two 
protein bands with molecular weights of 150 and 120 kD in 
nonreducing conditions) from human glioblastoma cells. 
However, as with Sonnenberg, they used a pepsin extract of 
human laminin coupled to the Sepharose. The fragment thus 
obtained is located in a different region of the laminin 
molecule from that of the YIGSR site, which binds the 67kDa 
receptor. Accordingly, they found no indication of a 
surface-labeled 67kDa protein in their affinity 
chromatography fractions, and the YIGSR peptide did not 
inhibit the binding of this receptor to laminin. 
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Secondly, there probably are many homologous peptide 
sequences amongst adhesive proteins, and thus fragments of 
these molecules could be recognized by different members of 
the integrin superf amily. Thus caution should be exercised 
in attributing a receptor role for components on the basis 
of their recovery from laminin fragment affinity columns. 
Lastly, the species from which the laminin was obtained may 
also influence the binding by laminin receptors. The laminin 
for the present study was isolated from the basement 
membrane of the Engelbreth-Holm-Swarm transplantable murine 
tumour. The Ae, Ble, and B2e chains of this laminin have 
been sequenced (Sasaki et al, 1988). Sequences of human A, 
Bl, and B2 chains were determined (Nissinen et al, 1991; 
Haaparanta et al, 1991; Pikkarainen et al, 1987, 1988) and 
found to be 75-85 % homologous to the corresponding mouse Ae, 
Ble, and B2 ct.a ins. Intact human placental laminin 
stimulates cell attachment of rat, human and mouse cells, 
with similar concentration dependency and kinetics to EHS 
laminin (Brown and Goodman, 1991). And although the 
microscopic form of human placental laminin is similar to 
the EHS molecule, some biological activities are not. Not 
only is the coiled-coil alpha helix in the long arm 
considerably more thermally stable than in EHS laminin, but 
also it is apparently not recognised by the same receptors. 
Initial studies indicate that alpha6/betal, for example, is 
not the maJor cell surface receptor for human laminin, 
either on murine or human cells (Goodman, 1992). Thus it 
would be important to carry out the isolation procedure for 
the platelet 67kDa receptor using a whole human placental 
laminin affinity column to verify the findings of the 
present work. Intact molecules from species other than 
mouse, and sources other than tumour basement membrane have 
not been available in quantities sufficient for cell biology 
until recently. A simple and rapid purification of tumour 
laminin was devised, and u~ed to isolate for the first time 
intact normal laminin from murine heart (Paulsson et al, 
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1987; Paulsson and Saladin, 1989). However, both murine and 
human E8 laminin fragments were used in the affinity 
chromatography, with identical platelet membrane components 
recovered in the eluate (Sonnenberg et al, 1991). 
Nevertheless, there are parallels of receptor pleiotropism 
in the binding of macrophages to laminin. Freshly isolated 
human peripheral blood monocytes adhere strongly to laminin, 
while that to fibronectin is weaker, with the weakest to 
collagen (Tobias et al, 1987) . With the use of virtually 
identical isolation procedures as used in the present study, 
the receptors bound to laminin in a dose-, time- and 
temperature-dependent manner and have a molecular weight 
identical to those of tumour cells and platelets (Huard et 
al 1986). They too are susceptible to trypsin proteolysis 
and are immunoprecipitated by antibodies to the 67kDa 
receptor (Mercurio and Shaw, . 1988). This evidence 
establishes its role as a receptor for laminin. However, 
large amounts of VLA-6, and moderate amounts of VLA-4 and 
VLA-5 are located on the membranes of macrophages, which 
also play a role in the adhesion (Hemler 1990). 
It is thus proposed that the integrin receptors VLA-6 and 
possibly GPIIb/IIIa, together with the non-integrin 67kDa 
receptor, are complementary systems governing the adhesion 
of a wide variety of cells to the laminin of basement 






A. Laminin molecule with cognate receptor for each binding 
site. 
B. Cell binding, all sites operative for maximal cell 
binding 
THE ROLE OF PLATELETS IN METASTASIS 
INTRODUCTION 
The spread of cancer is not a random event, but a series of 
sequential, interlinked steps, in which a tumour cell must 
complete a series of potentially lethal interactions with 
various host factors (Poste and Fidler, 1980; Jamieson et 



















[ ROLE OF PLATELETS J 
Once at the target site, cells invade tissues in a series of 
stages as proposed by Liotta et al (1977): 
i) Binding to components of the basement membrane. 
ii) Degradation of the basement membrane by hydrolytic 
enzymes derived from the neoplastic cells or host cells 
stimulated by the tumour. Defects of the basement membrane 
have been demonstrated adjacent to the invaders in the 
stroma (Burtin et al, 1982). 
iii) Extrusion of a pseudopodium through the defect in the 
basement membrane and locomotion into the matrix. 
THE ROLE OF PLATELETS IN METASTASIS 
There is some evidence to support the view that the presence 
of platelets has an adverse effect on tumour cell survival. 
Cytotoxic effects exerted by the arachidonate metabolites of 
platelets have been shown to enhance killing in a monocyte-
tumour cell cytotoxicity assay (Ibele et al, 1985). However 
there is overwhelming evidence that the interaction of 
platelets with tumour cells during the initial period of 
four to six hours, promotes the process in experimental 
metastases studies (Gasic and Gasic 1962, Gasic et al 1968, 
Pearlstein et al 1984, Crisman et al 1985). In vitro 
clonogenicity occurred 
thrombocytopenia. 
inversely with the degree of 
Central to the facilitating role of platelets, is their 
activation when coming into contact with metastatic cells 
that have entered the circulation, then aggregating around 
them to form a tumour cell-platelet embolus. 
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In cell lines this appears to principally involve either 
thrombin- or ADP-mediated activating mechanisms (Bastida et 
al, 1981, Bastida et al, 1984, Bastida et al, 1985). Sources 
of the agonists include: 
THROMBIN 
ADP 
Tissue factor on surface 
Contained within microvesicles 
Secretion 
Contained within microvesicles 
i) Generation of thrombin: 
This process, distinct from the intrinsic and extrinsic 
pathways of coagulation, is by tissue thromboplastin (Gordon 
et al 1979) and occurs within factor VIII- and factor VII-
deficient human plasma (Curatolo et al 1979). In the human 
glioblastoma cell line U87MG, thrombin-containing 
microvesicles are formed. These are 200nm in diameter on 
electron microscopic examination, and have both a 
procoagulant and a platelet-aggregant effect. In perfusion 
studies using a Baumgartner apparatus, these microvesicles 
produced large, complex platelet thrombi (Bastida et al 
1984) . 
ii) Release of Adenosine Diphosphate (ADP) 
This was found in suspensions of human lymphoma cells, 
certain of the Chang strains of human liver cells (Holme et 
al 1978), later in an undifferentiated murine cell line -
Hut20 (Bastida et al 1981), and demonstrated to cause rapid 
aggregation of platelets. 
iii) Release of Cathepsin B: 
This cysteine proteinase degrades pericellular protein at pH 
7. 1, is found within the lysosomes in murine B16 melanoma 
cells, and causes platelet aggregation (Honn et al, 1983). 
The variant with high metastatic potential B16-Fl0 had 
higher activity than the variant with low metastatic 
potential - B16-Fl. 
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The aggregation of platelets around the 
provides them with a protective shell, 
spread (Jamieson et al 1987). 




i) Shielding from host defense mechanisms 
polymorphonuclear leucocytes, T-lymphocytes 
mediated by 
and natural 
killer cells, which are important in preventing metastases 
(Hanna, 1982) . 
ii) Protection from the turbulence of the blood flow. 
iii) Platelets provide enzymes like heparan sulphate at 
metastatic sites, to assist in the degradation of 
extracellular matrix tissue (Oldberg et· al, 1980). This 
could be particularly important for cells of low metastatic 
potential which degrade matrix tissue less effectively than 
their more malignant counterparts, as has been demonstrated 
with Bl6 melanoma cell lines (Nakajima et al, 1983). 
iv) Increased vascular permeability facilitates the 
migration of tumour cells into parenchymatous tissues. This 
is provided by alpha granule constituents such as platelet 
basic protein (Paul et al, 1980), beta thromboglobulin, 
platelet factor 4, dense granule components like histamine 
and serotonin (Nachman, 1978) and prostaglandins (Honn et 
al, 1983). 
v) Chemotactic activity from platelet-derived growth factor 
released from the alpha granules assists in cell migration 
into the subendothelial tissues (Grotendorst e~ al, 1981). 
vi) Stimulatory peptides promoting mitogenic activity, like 
platelet derived growth factor, transforming growth factor 
and epidermal growth factor-like peptide acting in concert 
(Assoian et al, 1984). 
The metastatic process is inefficient, fewer than 1% of 
radiolabelled tumour cells are viable 24 hours after being 
injected into the circulation of syngeneic mice, as a result 
of immune-surveillance mechanisms (Fidler 1973). The 
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protective and promotive mechanisms are thus likely to be 
important. They are summarized diagramatically below: 
Buffer turbulence 







Shelld from cytotoxic 
host cells 
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L_ Degradation of 
basement membrane and 
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A. Protective function of platelet shell within circulation. 
B. Promotive function at site of lodgement 
The relevance of the present work revolves around the 
process of lodgement of the embolus within vascular beds. 
The original postulate for the role of platelets was based 
on autopsy studies, where tumour cells were frequently found 
in association with platelet thrombi (Billroth 1878). These 
observations have been repeatedly confirmed over the years. 
Such thrombi were demonstrated with the use of micro-
cinematography in a rabbit ear chamber model 
and light and ul trastructural studies (Jones 






What remains controversial is the manner in which this is 
achieved. Two proposed mechanisms whereby platelets promote 









A. Lodgement of the embolus, platelets reacting with 
vessel wall constituents, followed by invasion. 
- B. The initial interaction of the tumour cells with the 
vascular endothelium, with platelet activation following 
invasion and exposure of the subendothelial tissues. 
There is support for both these mechanisms. For B: Rats made 
thrombocytopenic with anti-platelet serum have a 53% 
reduction of rat fibrosarcoma cells in the hepatic biopsies 
after direct intra-portal injection (Skolnik et al, 1984). 
However, previous studies by this group did not identify any 
platelet involvement in the early phases of their 
experimental metastasis model when viewed by electron 
microscopy (Bagge et al, 1983) . The enhancing effect was 
thus thought to be due to amine release upon aggregation 
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after initial tumour cell adhesion to subendothelial 
tissues. In other studies (Crissman et al 1985, 1988), 
minimal platelet association or activation was evident in 
the first 2 minutes, when the tumour cells were already in 
juxtaposition to the endothelial cells. Aggregation 
commenced within 2 to 10 minutes, with the formation of a 
stable thrombus in the next 4 hours. This supports the 
proposal that the thrombus is generated secondary to 
lodgement, adhesion and penetration of the neoplastic cells, 
exposing the subendothelial tissues, which activates 
platelets. Tumour cells produce cytokines, including 
interleukin-1, which induce the expression of surface 
glycoproteins like ICAM-1 and E-selectin by the vascular 
endothelium (Rice and Bevilacqua, 
1991), thus promoting their own 
1989, Hawrylowicz et al, 
adhesion. 
receptors for matrix proteins 1 ike laminin 
Their surf ace 
(Liotta, 1986) 
would allow direct interaction with subendothelial tissues. 
However mechanical entrapment of the embolus as the initial 
process is also supported. Using Walker 256 cell infusions 
into Sprague-Dawley rats, Jones et al (1971) noted that at 2 
minutes they were loosely attached to the endothelium or 
lying free in the circulation, surrounded by loose clusters 
of platelets, developing into compact masses in 2 hours. By 
3 to 8 hours the cells were still completely intravascular, 
with very little breaching of the endothelium and basement 
membrane. This only became apparent after 9 to 14 hours, at 
a stage when the platelets had virtually disappeared. In 
other studies, inoculated melanoma cells were associated 
with platelets and fibrin in the early stages, and only 
slightly attached to the endothelial cells of lung 
capillaries (Lapis et al, 1988). The latter then retracted, 
and after the tumour cells became tightly attached to the 
basement membrane, migrated over their surface, probably in 
response to the attraction of growth factors derived from 
the platelets. The tumour cells only started to penetrate 
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the basement membrane after they were covered by the 
endothelial cells. 
This mechanisms by which platelets could mediate this role 
are multiple: 
As seen with scanning electron microscopy, platelet 
membranes form an adhesive bridge between tumour cells and 
the subendothelial matrix, a phenomenon considered as 
critical for the process of invasion (Menter et al, 1987). 
- Release of serotonin to facilitate the widening of the 
diameter of the open endothelial intercellular junctions, 
which in their resting state, are 30-60nm in diameter, too 
small for the penetration of any cells (Simionescu et al, 
1978). The filipodia of the platelets could then penetrate 
these gap junctions, to cause retraction of the endothelium 
and damage to the basement membrane and submembranous 
tissues by its heparan sulphate degrading enzymes. 
B16 melanoma cell-stimulated platelets greatly enhance 
tumour cell adhesion to endothelial cell monolayers (Tohgo 
et al, 1990), causing retraction of the endothelial cells, 
allowing greater interaction of the tumour cells with the 
subendothelial matrix. 
THE RELEVANCE OF THE PLATELET LAMININ RECEPTOR 
The tumour cell-platelet embolus will have receptors for the 
most abundant glycoprotein of the basement membrane well 
represented on the surface. These could serve to anchor the 
thrombus to vascular beds, facilitating migration of the 
motile malignant cells through the basement membrane. Anti-
laminin antibodies decrease the coverage of vascular 
segments by platelets in flowing blood, with significant 
decreases in spreading and aggregation on the surface 
(Ordinas et al, 1992, detailed in confirmatory studies, Page 
76). These findings point to an important contribution of 
laminin receptors in the lodgement of platelet-tumour cell 
emboli. 
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THE RELEVANCE TO ONCOLOGY 
The essence of cancer research is to acquire insight into 
the fundamental mechanisms of oncogenesis, invasion and 
metastasis, with the hope of identifying specific 
biochemical factor5 that can be used in diagnostic or 
therapeutic strategies (Liotta, 1986). 
In their dissemination, a cardinal characteristic is the 
capacity of tumour cells to degrade basement membrane, which 
is greater than their counterparts at the primary site 
( Liotta et al, 1977) . Thus those carried to the sites of 
secondary spread are a distinct subpopulation with enhanced 
invasive potential. 
Therapeutic options must consider inhibition of each step in 
the sequence (Bastida, 1988) . The control of the platelet 
activation by antiplatelet drugs remains controversial 
(Cazenave et al, 1978; Zacharski, 1984; Jamieson et al, 
1987). The phosphodiesterase inhibitor, RA-233 (mopidamol) 
has been shown to limit progression of tumours in 
experimental models. RA-233 was also shown to be of benefit 
in a large trial of patients with cancer, but the it was not 
a controlled one (Zacharski et al, 1982). A later randomized 
VA Cooperative Study (CSP#l88) used chemotherapy with and 
without RA-233 in patients with carcinoma of the lung or 
colon. After a minimum of one year follow up, the drug was 
shown to be of benefit for only a single sub-group of 
patients - those with non-small cell lung carcinoma limited 
to one hemithorax (Zacharski et al, 1987). There thus 
appears to be a crucial need for more selective anti-
platelet agents. 
The thrust of the present work relates to the established 
pathophysiological feature at this stage of the metastatic 
process, that the tumour cells are surrounded by a shell of 
platelets. In their capability to insulate tumour cells from 
host defense mechanisms, and buffer the mechanical trauma of 
the turbulence of the flowing blood, the platelet shell 
contributes to their 




addition, they are 
degrade extracellular 
matrix tissue and increases vascular permeability, in this 
way enhancing their capacity to penetrate tissues. Growth 
factors promote their mitogenic and chemotactic activity, 
further assisting in cell invasion into the subendothelial 
tissues and clonal expansion. 
The metastatic potential of breast carcinoma cells has been 
correlated with the number of unoccupied laminin receptors 
on their surface membranes (Barsky et al, 1984a). Treatment 
with the relevant binding fragments markedly inhibits or 
abolishes spread in a non-toxic fashion (Barsky et al, 
1984b). Directing binding fragments at the platelets 
membrane would be of central importance, since it would 
interfere with the process at a critical point. The 
synthetic peptides which include the critical YIGSR sequence 
of the Bl chain which is recognised by the 67kDa receptor, 
have opened up exciting therapeutic possibilities. These 
peptides were used in a murine model of lung tumour 
colonization after the intravenous injection of Bl6Fl0 
melanoma cells ( Iv,:amoto et al, 1987) . They decrease the 
ability of these cells to attack and degrade basement 
membrane matrix, impairing their migration though it by over 
90%. Lung tumours were reduced by over 90%. Multiple 
intravenous administrations of polymers of the synthetic 
YIGSR monopeptide sequence, resulted in the reduction of 
lung colonies in experimental metastasis by over 80% (Saiki 
et al, 1989). 
This present study has uncovered yet another mechanism which 
could impact at the most critical point of haematogenous 
spread. A receptor has been found on the surface of the 
enveloping cell aggregate, critical for invasion by the 
cancer cells, allowing them to anchor to and penetrate 














A. Embolus in circulation 
B. Lodgement at site of secondary spread 
Together with impr::>ved means to control their activation, 
the effective blockage of the 67kDa receptor of platelets 
discovered here, will introduce a meaningful therapeutic 
advance in the fight against cancer. 
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